

The Glutathione System: A New Drug Target in Neuroimmune Disorders

Gerwyn Morris • George Anderson • Olivia Dean •
Michael Berk • Piotr Galecki • Marta Martín-Subero •
Michael Maes

Received: 4 January 2014 / Accepted: 31 March 2014
© Springer Science+Business Media New York 2014

Abstract Glutathione (GSH) has a crucial role in cellular signaling and antioxidant defenses either by reacting directly with reactive oxygen or nitrogen species or by acting as an essential cofactor for GSH *S*-transferases and glutathione peroxidases. GSH acting in concert with its dependent enzymes, known as the glutathione system, is responsible for the detoxification of reactive oxygen and nitrogen species (ROS/RNS) and electrophiles produced by xenobiotics. Adequate levels of GSH are essential for the optimal functioning of the immune system in general and T cell activation and differentiation in particular. GSH is a ubiquitous regulator of the cell cycle per se. GSH also has crucial functions in the brain as an antioxidant, neuromodulator, neurotransmitter, and enabler of neuron survival. Depletion of GSH leads to exacerbation of damage by oxidative and nitrosative stress; hypernitrosylation; increased levels of proinflammatory mediators and inflammatory

potential; dysfunctions of intracellular signaling networks, e.g., p53, nuclear factor- κ B, and Janus kinases; decreased cell proliferation and DNA synthesis; inactivation of complex I of the electron transport chain; activation of cytochrome c and the apoptotic machinery; blockade of the methionine cycle; and compromised epigenetic regulation of gene expression. As such, GSH depletion has marked consequences for the homeostatic control of the immune system, oxidative and nitrosative stress (O&NS) pathways, regulation of energy production, and mitochondrial survival as well. GSH depletion and concomitant increase in O&NS and mitochondrial dysfunctions play a role in the pathophysiology of diverse neuroimmune disorders, including depression, myalgic encephalomyelitis/chronic fatigue syndrome and Parkinson's disease, suggesting that depleted GSH is an integral part of these diseases. Therapeutical interventions that aim to increase GSH concentrations in vivo

G. Morris
Tir Na Nog, Bryn Road Seaside 87, Llanelli SA152LW, Wales, UK

G. Anderson
CRC Clinical Research Centre/Communications, Laurel Street 57,
Glasgow G11 7QT, Scotland, UK

O. Dean • M. Berk • M. Maes
Barwon Health, School of Medicine, Deakin University,
P.O. Box 291, Geelong 3220, Australia

M. Berk
Orygen Youth Health Research Centre, Poplar Road 35,
Parkville 3052, Australia

M. Berk
Centre of Youth Mental Health, University of Melbourne, Poplar
Road 35, Parkville 3052, Australia

M. Berk
The Florey Institute for Neuroscience and Mental Health, University
of Melbourne, Kenneth Myer Building, Royal Parade 30,
Parkville 3052, Australia

M. Berk
Department of Psychiatry, University of Melbourne, Level 1 North,
Main Block, Royal Melbourne Hospital, Parkville 3052, Australia

P. Galecki
Department of Adult Psychiatry, Medical University of Lodz,
Aleksandrowska 159, Lodz 91229, Poland

M. Martín-Subero
Department of Psychiatry, Hospital Germans Trias i Pujol, Carretera
de Canyet s/n. 08916, Badalona, Spain

M. Maes (✉)
Department of Psychiatry, Faculty of Medicine, Chulalongkorn
University, Rama 4 Road 1873, Pathumwan
Bangkok 10330, Thailand
e-mail: dr.michaelmaes@hotmail.com

include *N*-acetyl cysteine; Nrf-2 activation via hyperbaric oxygen therapy; dimethyl fumarate; phytochemicals, including curcumin, resveratrol, and cinnamon; and folate supplementation.

Keywords Glutathione · Oxidative and nitrosative stress · Inflammation · Cytokines · Depression · Myalgic encephalomyelitis · Chronic fatigue · Immune

Introduction

γ -L-Glutamyl-L-cysteinyl-glycine or glutathione is a tripeptide with multiple cellular functions. There are two forms of glutathione—the oxidized form (glutathione disulfide or GSSG) and the reduced form (GSH). Glutathione is a key antioxidant, either by reacting with reactive nitrogen species (RNS), reactive oxygen species (ROS), hypochlorous acid (HOCL), hydroxyl radicals (HO•), and other reactive species or via its role as an indispensable cofactor for numerous enzymes including the glutathione peroxidases and glutathione *S*-transferases [1].

Glutathione has several key functions in diverse cellular populations. The GSH/GSSG redox couple acts as a vital cellular redox buffer enabling the optimum performance of a myriad of redox sensitive biochemical and biophysical processes [1]. Glutathione is a key component of the antioxidant defenses in the cell and the detoxification of ROS and RNS [2]. *S*-Glutathionylation, i.e., the posttranscriptional addition of glutathione to protein cysteine, modifies the activity of many proteins, including intracellular signaling molecules, and inhibits the activity of many important enzymes. The glutathione-related redox state of cells plays an important role in the regulation of proinflammatory cytokines, including tumor necrosis factor- α (TNF α), interleukin (IL)-1 β and IL-6, and the activity of intracellular signaling pathways [3]. Glutathione has antiviral effects and can inhibit the replication of many viruses. Glutathione modulates the function of T cells and natural killer cells and regulates the processes enabling cellular proliferation, division, and apoptosis [2]. Glutathione plays a role in DNA synthesis, repair, and expression [4]. The function and survival of mitochondria is dependent on the glutathione system. Glutathione has important functions in the brain as an antioxidant and neuromodulator and promoter of neuronal survival. Glutathione acts as a neuromodulator of the glutamate ionotropic receptors, interacts with *N*-methyl-D-aspartate (NMDA) receptors, and protects against glutamate excitotoxicity [5]. These key functions explain why depletion of glutathione may be accompanied by dysfunctions in many organs and cell functions that are associated with the onset of neuroimmune disorders, including depression, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and Parkinson's disease.

This paper aims to discuss the numerous functions of glutathione in health and disease as well as to review the evidence for disorganization of the glutathione system in depression, ME/CFS, and Parkinson's disease before finally considering treatment approaches for restoring the normal function of the glutathione systems.

The Glutathione System

Synthesis and Basic Biochemistry


The synthesis of glutathione is a two-stage process, with each stage being dependent on the energy provided by the hydrolysis of adenosine triphosphate (ATP) [6]. The first and rate-limiting step is catalyzed by (γ -glutamylcysteine synthase (glutamate cysteine ligase) and involves the formation of a peptide bond between L-glutamic acid and the N terminal of L-cysteine. The second step involves the addition of glycine and is catalyzed by glutathione synthetase. Glutathione is mostly synthesized in the cytosol of the cells, where its concentration is some 2 orders of magnitude higher than in the extracellular environment [7]. Cytosolic glutathione is transported into mitochondria, the endoplasmic reticulum, and the nucleus where it exists in independent pools. The reduced form dominates in most cells or compartments but, in the endoplasmic reticulum, the oxidized GSSG form is predominant [8, 9]. A schematic representation of pathways involved in glutathione synthesis can be seen in Fig. 1.

Glutathione Peroxidases

Glutathione may also serve as a cosubstrate for glutathione peroxidases which are part of the cellular enzymatic antioxidant network responsible for scavenging organic and inorganic peroxides [10]. GSSG formed by these reactions (and others) may either be excreted or reduced to glutathione via the action of NAD(P)H-dependent glutathione reductase. For a detailed review of the biochemistry relating to the six isoforms of the selenium-dependent glutathione peroxidases, the reader is referred to the work of Sheehan et al. [11]. Conjugation with electrophiles is a major cause of glutathione depletion as is the export of GSH, GSSG, and GSH conjugates into the intracellular environment. Glycine and glutamate may be salvaged and reabsorbed following hydrolysis [12] but cysteine is lost and *S*-glutathione conjugates are metabolized to mercapturic acids before being excreted in bile and urine [13].

Glutathione *S*-Transferases and Glutaredoxins

Glutathione *S*-transferases are enzymes that catalyze the biotransformation of otherwise genotoxic or carcinogenic molecules of endogenous or exogenous origin by conjugation with



Abbreviations.

B12: vitamin B12.
BHMT: betaine homocysteine methyltransferase.
DMA: dimethylarsinic acid.
DP: dipeptidase.
GGT: γ -glutamyltransferase.
GSH: glutathione.
GSSG: oxidized glutathione.

InAs: inorganic As.
MMA: monomethylarsonic acid.
MTR: methionine synthetase.
SAM: S-adenosylmethionine.
SAH: S-adenosylhomocysteine.
THF: Tetrahydrofolate.

Fig. 1 Glutathione (GSH) is normally produced de novo via a two-step reaction. In the first step, γ -glutamylcystine is the product of a reaction between cysteine and glutamate enabled by the enzyme glutamate cysteine ligase (GCL). Glycine is then added to produce GSH through glutathione synthetase. GCL activity and cysteine levels are the two rate-limiting factors in GSH synthesis. The activity and expression of GCL is regulated by GSH or more accurately the GSH/GSSG ratio via a number of redox-sensitive pathways in response to a GSH shortage or oxidative stress. Other mechanisms exist to maximize the regeneration of GSH and minimize the concentration of GSSG. Such mechanisms involve the regulation of cysteine importation and the exportation of GSH. Another mechanism involves the upregulation of γ -glutamyl transpeptidase (GGT). This enzyme located on the outer membrane of cells transfers the glutamate from GSH to an amino acid acceptor molecule. The synthesis of GSH is also associated with the trans-sulfuration pathway, which synthesizes cystathionine from homocysteine and serine and leads to the formation of cysteine. The S-adenosylmethionine (SAM)/S-adenosyl homocysteine (SAH) ratio acts as sensor mechanism which results in the diversion of homocysteine into the trans-sulfuration pathway resulting in increased GSH synthesis. The reaction from 5-methyl-tetrahydrofolate (5-methyl-THF) to tetrahydrofolate (THF) transfers a methyl group to homocysteine thereby forming methionine

glutathione [2]. Two families of supergenes encode glutathione S-transferases—16 genes code for soluble glutathione S-transferases and 6 genes code for microsomal glutathione S-transferases [14]. These enzymes are divided into eight classes based on sequence homology—alpha (GSTA), theta (GSTT), mu (GSTM), omega (GSTO), kappa (GSTK), zeta (GSTZ), sigma (GSTS), and pi (GSTP) [15].

Glutaredoxins (GRXs) are glutathione-dependent redox enzymes that utilize glutathione's reducing power to catalyze

disulfide reductions in the presence of glutathione reductase [16]. They are highly specific in their actions and enable the displacement of glutathione from mixed disulfides according to the reaction $\text{GSH} + \text{protein-SSG} = \text{GSSG} + \text{protein-SH}$ [17]. Glutaredoxins GRX 1 and GRX2 are located in the cytosol [18] and the intermembrane space of mitochondria [19].

Glutathione and Oxidative and Nitrosative Stress (O&NS) Detoxification

Glutathione plays a major role in the detoxification of RNS and ROS, and as such is an indispensable component of the cellular antioxidant defenses [2]. Cellular glutathione is consumed by oxidation conjugation and hydrolysis [7, 11, 20]. Glutathione can react with ROS/RNS and radical molecules, such as $\text{RO}\cdot$, HOCL , and $\text{HO}\cdot$. Glutathione may be directly oxidized by $\text{HO}\cdot$ and peroxynitrite (ONOO^-) producing thiyl radicals [21–23]. Glutathione plays a pivotal role in the detoxification of NO and products of ROS-induced lipid peroxidation, such as 4-hydroxynonenal (4HNE) and malondialdehyde (MDA) [24, 25]. The GSH/GSSG redox couple together with the NAD(P)/NAD(P)H and FAD/FADH redox couples are responsible for maintaining the redox state of the cell [26, 27]. Glutathione in the nucleus is responsible for maintaining the required redox state of thiol proteins involved in DNA synthesis and repair [28].

Glutathione and glutathione S-transferases via their role as electrophile scavengers can act as indirect regulators of biochemical pathways modulated by these molecular entities. One of the pathways so regulated is the stress-mediated pathway whose performance is governed by 4HNE levels, a preferred substrate for one of the alpha class glutathione S-transferases [29]. These enzymes thus have a crucial role in protecting cells by enabling the elimination of toxic chemicals, e.g., byproducts of oxidative stress [30, 31], including oxidized DNA and catechols. They do so by promoting electrophile conjugates with glutathione and directly inhibiting hydrogen peroxide (H_2O_2)-induced lipid peroxidation [31].

Perhaps unsurprisingly, polymorphisms in glutathione S-transferases are prime suspects in the cause of many diseases, as is the case with GSTTi and GSTMi where polymorphisms stemming from deletions results in loss of enzyme activity [15, 32]. Downregulation or inactivated GSTPi as a result of polymorphisms likely increases genomic damage when an individual with this genotype exposed to carcinogens due to reduced detoxification capacity [15, 33]. These polymorphisms are implicated in the development of autoimmune disorders including systemic lupus erythematosus stemming from prolonged exposure to toxins in the environment [34], as

well as psychiatric disorders such as schizophrenia, autism, and bipolar disorder [35–38].

Glutathione and glutathione *S*-transferases are important players in xenobiotic detoxification which may be usefully considered as consisting of three interrelated phases. The first is biotransformation or bioactivation mediated via cytochrome P450 and other monooxygenases, predictably known as phase 1 enzymes. Six cytochrome p450 enzymes (with CYP3A4 and CYP2D6 being the most important) are responsible for metabolizing 90 % of prescription drugs and this class of enzymes may be inhibited or induced by xenobiotics leading to adverse reactions or failure of therapy [39]. The first step of the detoxification process can paradoxically generate electrophiles or nucleophiles that are often carcinogenic or toxic [40]. The major metabolic role of glutathione *S*-transferases is the detoxification of these reactive electrophiles by catalyzing their conjugation (second phase) with glutathione [41, 42]. This process usually results in a reduction of electrophile reactivity and increases the water solubility of the compounds favoring their elimination (third phase) thereby greatly reducing the potential of damaging interactions between these chemical entities and nucleic acids and proteins.

Glutathione and Post-transcriptional Modification of Proteins

Prolonged elevation of oxidative stress leads to the chemical modification of protein thiols either by the addition of NO moieties in a process described as nitrosylation (protein–SNO or protein–NO) or the transferase enzyme-driven addition of glutathione to sulphydryl or sulfenic acid groups termed glutathionylation (protein–SSG). Both processes are important examples of post-translational modification and have a wide range of effects on protein structure and function as well as conferring resistance to further perhaps irreversible oxidative damage. We now consider these processes in more detail.

Response of Cysteine to Elevated O&NS

Production of thiyl (or thiol or mercapto radicals) radicals (RS) may follow exposure of cysteine groups to ROS and RNS. These are very short-lived derivatives that react with protein–SH molecules to form protein–SSG. Exposure of cysteine to ROS and RNS also results in the genesis of sulfenic acids (RSOH), which are highly unstable entities that rapidly undergo further oxidation to sulfinic or sulfinic acids, or react with glutathione to produce protein–SSG [43, 44]. Sulfenic acid is readily reduced by a favorable change in the redox state of the cell or via the action of a wide range of reductases [45]. The oxidation of cysteine residues may in some circumstances be beneficial in that the reaction may act as a redox sensor but the normal outcome is the inactivation of

a thiol protein especially if the cysteine group is integral to its function.

Glutathionylation

An alternative to the action of reductases in reversing oxidative damage to protein thiols is the addition of glutathione in a process known as *S*-glutathionylation [46, 47]. The glutathylation process is enabled by a ROS induced elevation of two forms of glutaredoxins, GRX1 and GRX2 of the pi class of glutathione *S*-transferases, which catalyze the conjugation of glutathione to cysteine, sulfenic acid or other sulphydryl moieties [48]. Glutaredoxins catalyze both glutathionylation and deglutathionylation because GRX catalytic mechanisms are bidirectional with resultant direction being decided by the levels of GSG, GSSG, protein–SH, and protein–SSG.

The activities of a wide range of proteins may be up or downregulated by *S*-glutathionylation. Cytoskeletal thiol proteins are particularly susceptible to glutathionylation and other susceptible protein clusters include kinases and other cellular signaling proteins and proteins involved in energy production and calcium homeostasis [49]. *S*-glutathionylation inhibits the activity of many enzymes and functional proteins, for example phosphofructokinase [50], glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [51], creatine kinase [52], nuclear factor kappa B (NF- κ B) [53], I κ B kinase (IKK) [54], protein phosphatase 2A [55], mitochondrial complex I [56], mitochondrial complex II [57], protein kinase A [58], and matrix metalloproteinase [59].

The glutathionylation status of a protein–SH ultimately depends on the ratio of GSH/GSSG concentrations [47]. The presence of chronic oxidative stress leads to the glutathionylation of a wide range of proteins and this reaction may promote or impair their function [60]. However, overall glutathionylation is a mechanism aimed at preventing irreversible damage of thiol proteins as a result of elevated ROS [2]. Glutathionylation of proteins containing cysteine in complex I of the electron transfer chain is a signaling mechanism that may dampen aerobic metabolism during periods of low antioxidant status. This leads to inhibition of complex I which in turn impairs electron flow ultimately decreasing downstream ROS formation [61].

Nitrosylation

Another process of posttranscriptional modification of thiol proteins is the addition of a NO group, known as nitrosylation [62]. Cysteine sulphydryl groups located on glutathione and proteins become nitrosylated in physiological and pathological conditions forming protein–GSNO and protein–SNOs, respectively [63, 64]. Various reactions between ROS and RNS produce a range of metabolites of which N₂O₃ is the

main nitrosylating species [65]. The ready reversibility of any reaction involving NO (nitrosylation and denitrosylation) by virtue of dative bond formation underpins the molecules role as a classical second messenger [66]. The development of GSNO-induced glutathionylation versus nitrosylation is probably dependent on the localized redox environment of the transformed cysteine (Cys) residues [67].

Glutathionylation Versus Nitrosylation

Glutathionylated and nitrosylated proteins coexist in an environment of oxidative stress and an exchange of these modifications between proteins occurs with reasonable frequency. There are major differences between proteins in susceptibility to each modification [68]. On some occasions, both modifications will impair protein function but on others different affinities of protein thiols for each modification leads to highly specific consequences. Glutathionylation or nitrosylation reactions tend to occur in different cellular compartments with nitrosylation being more dominant where ROS and RNS are created such as in mitochondria and the endoplasmic reticulum. In fact, mitochondrial ROS generation may be important for the nitrosylation reaction to occur [69].

Transcription factors such as p53 and NF- κ B are redox sensitive due to the presence of cysteine residues which are vulnerable to glutathionylation. The effects of this process on the function of these transcription factors are quite subtle and varied. For example, glutathionylation does not impede the activation of NF- κ B or its translocation to the nucleus but glutaredoxin-mediated glutathionylation of cysteine residues on the p65 and p50 subunits inhibits their binding to DNA and hence disable the ability to instigate the transcription of survival genes [70, 71]. Glutathionylation of p53 and NF- κ B has serious consequences as both transcription factors are important components in energy metabolism and immune homeostasis [72, 73]. Nitrosylation of the p50 and p65 subunits of NF- κ B suppresses the binding of the transcription factor to DNA causing its inactivation [74, 75]. Nitrosylation of cysteine groups also impairs multiple steps involved in NF- κ B activation [76].

Glutathione in Immune-Inflammatory Pathways and Cytokine Signaling

Glutathione and Cytokines

The redox state of cells plays a cardinal role in the regulation of IL-1 β , IL-6, and TNF α transcription and in the modulation of the signaling pathways activated by these cytokines [77]. MAPK-dependent cytokine expression and signaling is under redox control and glutathione depletion enhances both the transcription and deleterious effects of cytokines and

conversely elevated levels of glutathione and cysteine have been shown to suppress transcription of proinflammatory cytokines [77, 78]. The GSH/GSSG ratio regulates the transcription of IL-6, IL-8, IL-4, and TNF α [79–81]. On the other hand, proinflammatory cytokines reduce glutathione synthesis transport and recycling [82, 83].

An examination of IL-1 β transduction serves to illustrate the pleiotropic effects of glutathione on proinflammatory signaling. IL-1 signaling consists of three phases involving initial complex formation with NF- κ B followed by its activation and finally its translocation to the nucleus ultimately provoking gene transcription [76]. A range of thiol-oxidizing compounds have the capability of inhibiting all three phases but their oppressive actions would normally be neutralized by glutathione [84]. However, glutathione is clearly not the sole enabler of NF- κ B activation as this transcription factor is also activated by oxidative stress [84]. In a highly oxidative environment, however, NF- κ B transcription is enhanced by hyperexpression of glutathione peroxidases, indicating an overall inhibitory role for glutathione. As discussed, glutathione also modulates NF- κ B-instigated signaling via glutathionylation thereby impeding DNA binding [84]. All in all, the evidence indicates that the precise redox state is crucial in promoting or inhibiting the activation of NF- κ B activation. Glutathione depletion is thus likely to produce a number of different modulating influences on the activation of this transcription factor.

Glutathione and Regulation of the Immune Response

Glutathione and Viral Replication

Glutathione-, selenium-, and glutathione-dependent enzymes are all involved in antiviral defenses. Glutathione can inhibit the replication of Lenti retroviruses [85], delta retroviruses [86], gamma retroviruses [87], influenza viruses [88], and Herpes simplex type 1 [89]. Glutathione inhibits HIV by repressing the production of the p24 gag protein and by doing so inhibits budding, infectivity, and viral release. Glutathione also inactivates the Gp120 envelope protein, which is very vulnerable to glutathione attack because it is rich in structural disulphide bonds [85, 90]. The inhibition of viral envelope proteins is one of the mechanism by which glutathione inhibits the production of influenza or Sendai virus [85, 88, 89]. Dengue virus infection directly depletes glutathione, and this ability is a conserved evolutionary mechanism favoring its replication. Elevated levels of glutathione inhibit the replication of this virus [91, 92].

Glutathione and T Cell Activation

The activation and proliferation of T cells requires the existence of a strong intracellular and extracellular reducing

environment [93, 94], which is mainly engineered by antigen-presenting cells, especially dendritic cells [92, 95, 96]. When dendritic cells are stimulated by T cells, they increase their uptake of cystine by deploying x_c^- cystine transporter receptors and extrude cysteine (the reduced form of cystine) into the environment. Although extracellular cystine is abundant, naïve T lymphocytes lack the machinery to transport cystine, with any degree of efficiency and hence depend on cysteine derived from dendritic cells to meet their metabolic needs [97–99]. Cysteine derived from dendritic cells is required by T cells for synthesis of glutathione, ultimately providing the reducing power enabling DNA synthesis [100] and allowing progression from G₁ to the S phase [101, 102]. By controlling cystine/cysteine levels, dendritic cells are able to affect intracellular glutathione levels and subsequent redox signaling pathways in T cells [98].

Redox modulation is also part of the immunosuppressive armory deployed by T regulatory (Treg) lymphocytes in mediating their effects when activated. Tregs impair the synthesis of glutathione in dendritic cells by inhibiting the expression of gamma-glutamyl transpeptidase (γ GT), the rate-limiting enzyme for glutathione synthesis. Tregs also successfully compete for and ultimately oxidize cysteine-depriving effector T cells their major source of essential cysteine. Tregs also appear to block the redistribution of glutathione from the nucleus to the cytoplasm in effector T lymphocytes which is an essential step in their proliferation [103].

Glutathione and T Cell Differentiation Patterns

Glutathione levels in antigen-presenting cells govern which pattern of differentiation predominates [104, 105]. Glutathione plays a crucial part in enabling the growth-promoting properties of IL-2 [106] by regulating the internalization, binding, and degradation, of this cytokine as well as IL-2-driven T-cell proliferation. The weight of evidence suggests that immune responses are optimally at intermediate glutathione concentrations that support efficient DNA synthesis and do not inhibit IL-2 production [107]. For example, IL-2-activated natural killer (NK) cells need a reducing environment, provided by de novo synthesis of glutathione, in order to proliferate and perform their normal functions [108]. Intracellular glutathione concentrations largely govern the replication, differentiation, and growth of IL-2-reactive cytotoxic T-lymphocytes [109, 110].

Glutathione and Cell Proliferation

During normal physiology, glutathione becomes localized to the nucleus when cells are actively dividing [111, 112]. The activity of nuclear proteins especially telomerase is dependent on GSH/GSSG. Changes in telomerase activity lead to

changes in the activity of crucial cell cycle proteins id2 and E2F4 [111]. Glutathione has a key role as a redox sensor at the commencement of DNA synthesis and glutathione levels play a crucial role in maintaining nuclear architecture by ensuring the requisite redox environment for ensuring DNA integrity prior to replication. Glutathione also influences proteosomal protein degradation in the nucleus and exerts epigenetic control on histone function and chromatin structure prior to replication by reducing the number of disulphide bonds on nuclear proteins and hence generating a reducing environment [111–113]. Glutathionylation and oxidation of nuclear proteins form the basis of reversible mechanisms for regulating cell proliferation repair and state of DNA compaction [112]. Chromatin by virtue of the cysteine motif on histone 3 (H3) is redox sensitive. The level of glutathionylation increases during cell division resulting in loss of nucleosomal stability and the formation of a more lax decompacted chromatin structure [114].

In general, the cell cycle involves a change from a reduced environment during proliferation and differentiation to a more oxidized milieu when cells undergo apoptotic cell death [115]. Glutathione has multiple means of influencing cell proliferation. Elevated levels of glutathione lead to the inhibition of p38 MAP and Janus kinases [116]. ROS, mainly in the form of hydrogen peroxide, and glutathione both play an important part in regulating the cell cycle. High hydrogen peroxide levels activate MAP kinases and NF- κ B leading to cell necrosis or apoptosis but at a lower dose hydrogen peroxide activates transcription factors such as nuclear factor (erythroid-derived 2)-like 2 (Nrf-2), which is a key regulator of glutathione synthesis. So, when ROS is produced at low concentrations, glutathione is synthesized and cellular proliferation occurs [117]. Given the influence of glutathione and glutathionylation on the activity of immune-inflammatory pathways, it is perhaps not surprising that the GSH/GSSG ratio and glutathionylation of proteins are key regulators of apoptosis [118, 119].

Glutathione and Mitochondria

Glutathione, Redox Homeostasis, and Mitochondrial Survival


The function and survival of mitochondria is dependent on the glutathione system. Mitochondria are a major site of cellular ROS generation in spite of the presence of a broad wide array detoxifying enzymes and antioxidants. Mitochondria produce over 90 % of total cellular ROS in some cells [120]. Mitochondria are thus the organelles with the greatest vulnerability to corrosive damage by free radical species such as hydrogen peroxide and superoxide [121, 122]. There are other mitochondrial sources of ROS apart from the electron transport chain. These sources include glycerol 3-phosphate

dehydrogenase, α -ketoglutarate dehydrogenase, mitochondrial NADPH oxidase (NOX4), monoamine oxidase, etc. [123–128]. Hydrogen peroxide is being continually produced by the electron transport chain. When conditions are in a state of redox balance, the amount of hydrogen peroxide exported into the cytoplasm is restrained by the action of matrix peroxidases [129] and glutathione peroxidases [130]. However, both the mitochondrial and cytoplasmic redox environments make an important contribution to maintaining redox homeostasis and the net rate of ROS accumulation within the cell is dependent on the interaction between the GSH/GSSG in the cytoplasm and the regeneration of glutathione in the mitochondrial matrix [130].

The optimum function and indeed the very survival of mitochondria are wholly dependent on the coordinated activity of the glutathione, glutaredoxin, and thioredoxin systems which act cooperatively to ensure continual maintenance and repair [131]. Redox sensors located in the cell and mitochondria have the capability of detecting dynamic perturbations in ROS concentrations and act to adjust antioxidant defenses in the face of intracellular or intercellular stressors which threaten to disrupt the redox balance in the mitochondria or cytosol [130–133].

The Glutathione System and Other Redox Couples In Mitochondria

The mitochondrial matrix, the inner membrane space, and the cytosol contain pools of segregated but interactive redox couples, e.g., NADPH/NADP, NADH/NAD, GSH/GSSG, and thioredoxin (Trx)/TrxSS [134, 135]. The thioredoxin and glutathione systems are the main hydrogen peroxide scavengers in all mitochondria. The protective properties of the glutathione system are conferred by the actions of glutathione-*S*-transferase and glutathione peroxidase (GPX)-4. The concentration of glutathione (GSH + GSSG) is 100 to 1,000 times higher in comparison to any other redox buffering system including thioredoxin so that the intracellular GSH/GSSG pool dominates the redox environment [136]. As such, the glutathione system is the primary protector of mitochondrial membranes against oxidative damage. The glutathione and glutaredoxin systems function cooperatively to reduce protein disulphides formed as a result of increased GSSG formed as a result of a chronic oxidative environment. Glutaredoxin acts to reduce protein disulphides and restore their conformation and function [137]. The thioredoxin system also plays an important part in reducing a range of protein disulphides [138] and also supplies hydrogen atoms used in the reduction of hydrogen peroxides and lipid peroxidases [139]. Figure 2 depicts the role of the glutathione antioxidant system in protecting mitochondria against the ravages of ROS.



Abbreviations.

ETC superoxide: electron transport chain superoxide.

Fe: Iron.

GSH: glutathione.

GSSG: oxidized glutathione.

H₂O: water

H₂O₂: hydrogen peroxide.

SOD: superoxide dismutase.

Fig. 2 Glutathione (GSH) and antioxidant enzymes, including superoxide dismutase (SOD), glutathione peroxidase, catalase may reduce the reactive oxygen species (ROS), which are produced through activity of the respiratory chain in the mitochondria. Loss of glutathione in mitochondria predisposes to pathology as the glutathione peroxidase enzymes require GSH as a cofactor. GSH is also unique in its ability to detoxify hydroxyl radicals. In an environment of low GSH, ROS levels rise and the loss of glutathione peroxidase activity is relatively more important in mitochondria which normally lack catalase. Ultimately, the excessive production of hydrogen peroxide and hydroxyl radicals in mitochondria will lead to damaged mitochondrial DNA, lipids, and proteins compromising mitochondrial function and ultimately necrotic cell death

Role of Glutathione in the Central Nervous System

Glutathione, a Glutamate Receptor Modulator

Glutathione is the most plentiful peptide in the brain and spinal cord and is present in glial cells and neurons as well as in intracellular spaces [140, 141]. Glutathione in its oxidized and reduced forms exerts the majority of its effects in the central nervous system (CNS) by interacting directly or indirectly with glutamate receptors. There are two families of glutamate receptors; metabotropic and ionotropic receptors [142]. The latter receptors are classified as NMDA, 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) or kainate receptors [142, 143]. These receptors are gated ion channels which open in response to the binding of a suitable ligand molecule such as the amino acid glutamate to allow passage of sodium or calcium ions. This flow of ions causes depolarization of the plasma membrane and the genesis of an electrical current. Chronic hyperstimulation of ionotropic receptors induces pathology by mediating the development of excitotoxicity through calcium and O₂NS mediated processes [144, 145].

Each of the three amino acids contained in glutathione is able to interfere with glutamate-mediated neurotransmission through both direct and indirect receptor modulation. The

glutamate group can bind to all types of glutamate receptor. The cysteine-based thiol group affects the redox state of those receptors, while glycine is actually an NMDA receptor agonist.

GSH and GSSG at physiologically normal concentrations both inhibit the glutamate binding to synaptic membranes [5, 146, 147]. Glutathione acts as a neuromodulator by displacing ligands of the glutamate ionotropic receptors from their binding sites and modulating the entry of calcium ions into ionophores regulated by NMDA receptors [148]. Glutathione, at millimolar concentrations, may interact with the redox sensitive site of NMDA receptors [149, 150] and such binding likely plays an important role in modulating neuroplasticity [151]. Glutathione displaces glutamate, via its glutamyl moiety, largely from AMPA receptors. GSH and GSSG, depending on their concentrations, can also displace AMPA and kainate from their respective receptors [152, 153]. Glutathione appears to confer neuroprotection against excitotoxicity and maintains intracellular Ca^{2+} homeostasis [154, 155]. GSH and GSSG ameliorate neuronal damage resulting from chronic NMDA receptor activation [156].

Glutathione and the Cystine/Glutamate Antiporter System in the Brain

There are two main types of glutamate transports in the CNS. The first is the excitatory amino acid transporter and the second is the x_c^- cystine/glutamate antiporter system. We will now discuss these in a little more detail in order to better highlight the adverse effects of low glutathione on the integrity and functioning of the brain. The excitatory amino acid transporters enable the uptake of glutamate against a concentration gradient [157] and prevent excessive glutamate receptor activation, which can lead to prolonged excitotoxicity and ultimately neuronal cell death. The excitatory amino acid transporters (EAAT1 and EAAT2) are mainly astrocytic transporters responsible for maintaining intracellular glutamate below neurotoxic levels [158]. The excitatory amino acid transporter EAAT2 is held to be responsible for some 90 % of glutamate uptake under normal conditions [159, 160]. Astrocyte excitatory amino acid transporter activity is much higher compared to that of microglia [161]. The x_c^- cystine/glutamate antiporter allows the uptake of extracellular cystine (for glutathione synthesis) in exchange of intracellular glutamate [162]. The optimum function of this system is crucial for the homeostatic control of cysteine and glutamate levels [163]. The expression of the x_c^- cystine/glutamate antiporters in the CNS is confined to astrocytes [164] and microglia [165]. Through astrocytic glutamate efflux the x_c^- antiporter may allow the targeting of glutamate to neuronal sites, allowing glutathione synthesis to modulate neuronal activity. Microglial x_c^- antiporter expression is important in the uptake of cystine for glutathione synthesis particularly during

activation by lipopolysaccharide (LPS) where the density of x_c^- antiporters is increased on the surface of activated microglia [166]. This may damage surrounding neurons by secreting glutamate at the same time as importing cystine to bolster the cells antioxidant defenses.

Depleted Glutathione: Consequences and Clinical Relevance

Consequences of Depleted Glutathione

Given the key roles of glutathione discussed in the previous sections, it is not surprising that glutathione depletion causes many perturbations in cell and organ functioning and is associated with the onset of neuroimmune disorders such as depression and ME/CFS. We will now review some of the effects of glutathione depletion before reviewing the evidence alluding to the existence of O&NS and a dysregulated glutathione system in neuroimmune disorders.

As mentioned above, the glutathione system is the most important protectant in the detoxification of ROS and RNS and as such is a vital component of the cellular antioxidant defenses [2, 167]. Glutathione reacts directly with different radical molecules and may be directly oxidized by $\text{HO}\cdot$ [168, 169] and peroxynitrite [170, 171]. Glutathione is involved in the detoxification of NO. Products of ROS-induced lipid peroxidation, such as 4HNE and MDA [172, 173], and a range of other metabolites produced by oxidative damage [174, 175]. A compromised glutathione system therefore leads to the development of chronic O&NS occurring in neuroimmune diseases [167, 176, 177].

The consequences of glutathione depletion on immune-inflammatory responses heavily depend on the nature of the proinflammatory mediators dominant in any given cellular environment. Cytokine regulation and reduced glutathione are intimately interlinked. The GSH/GSSG ratio determines the activation level of the JNK and MAPK pathways and thus the transcription of proinflammatory cytokines [178]. The redox state of the cell and the GSH/GSSG ratio govern the transcription of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and $\text{TNF}\alpha$ also plays a major part in the modulation of the signaling pathways activated by these cytokines [3, 79, 179]. Thus, glutathione depletion not only enhances the transcription, but also the deleterious effects of these cytokines [78]. The weight of evidence suggests that lowered levels of glutathione may suppress immune responses [180–183].

Depleted glutathione levels dramatically impair proliferation, DNA synthesis, and cytotoxic activity of T lymphocytes and may lead to a Th2 polarized immune system [101, 111, 167, 184, 185]. Glutathione peroxidase depletion additionally inhibits Th2 and Th17 differentiation of activated naive T cells [186]. Glutathione depletion also contributes to increased

blood-brain barrier permeability observed in neuroimmune disorders [187], thereby further increasing central immune-inflammatory processes by potentiating immune cell extravasation over a compromised blood-brain barrier.

As described above, many transcription factors are also redox sensitive including inactivation of p53 [188] and NF- κ B [189]. NF- κ B and p53 are vital players in the regulation of the immune response and energy production [72]. Glutathione levels also modulate signal transduction pathways within T lymphocytes involving AP-1 and tyrosine phosphorylation [190]. Glutathione depletion can also modulate inflammatory cascades by affecting the Janus kinase and STAT3 pathways [191]. In a depleted glutathione environment, glutaredoxin dissociates from signal-regulating kinase resulting in c-Jun N-terminal kinase activation leading to cyclo-oxygenase-2 induction and the production of prostaglandin E_2 [192–194].

The consequences of glutathione depletion reflect how redox mechanisms regulate DNA synthesis in G_1 phase and mitosis [195] and how glutathione depletion impairs the proliferation of all cell types [196, 197]. Reduced glutathione levels prevent the shift from G_1 to the S phase in the cell cycle, thereby decreasing cell proliferation [198]. Glutathione levels are high in cells preparing to divide or entering the mitotic phase but much lower in cells in the G_0/G_1 phase [199].

Glutathione depletion impairs mitochondrial function and ATP production by inhibiting complex I of the electron transport chain [200]. Since glutathione biosynthesis is an energy-dependent process [2], mitochondrial dysfunction significantly depletes glutathione production thereby further exacerbating oxidative damage which further impairs electron transport chain activity. Hence, glutathione depletion is almost certainly a major contributing factor to the progressive nature of mitochondrial diseases [200–202]. Glutathione levels in those with confirmed syndromic and nonsyndromic mitochondrial diseases are dramatically lower than those observed in healthy controls [203–205] even to the point of being undetectable [200]. The weight of evidence indicates that glutathionylation impairs complex I activity compromising energy production [206, 207]. Glutathione depletion also impairs the function of proteins regulating calcium homeostasis and energy generation [208].

Glutathione depletion may ultimately drive cytochrome c release and mitochondrial death [209]. In healthy neurons, cytochrome c is held inactive by increased glutathione [210]. ROS-independent glutathione depletion leads to the inhibition of sphingomyelin synthase activity, the activation of caspases, and ceramide generation [211, 212]. Additionally, glutathione loss impairs the canonical NF- κ B signaling pathway resulting in the sensitization of cells to apoptosis [213, 214]. Glutaredoxins also regulate the function of numerous proteins which play critical roles in the regulation of apoptosis by

catalyzing deglutathionylation and glutathionylation, such as NF- κ B, procaspase-3, Fas, and ASK1. Prolonged elevation of O&NS causes oxidative modifications of crucial Cys residues located in these apoptotic mediators, provoking protein-SSG generation and hence altering protein activity and apoptotic signaling [215]. Mitochondria form the central hub of cellular energetics and apoptotic processes, with the intimate bidirectional relationship between the glutathione system and mitochondria crucial to cellular functioning.

Depletion of glutathione can invoke the apoptotic machinery even in the absence of elevated O&NS [119, 216]. In different cell types, glutathione depletion participates in the onset of programmed cell death following numerous apoptotic signals [118, 216]. Prolonged glutathione depletion leads to JNK activation and an increase in expression of programmed death receptor 5 [217, 218] and Fas-mediated increase in mitochondrial membrane permeability [219]. Glutathione depletion may also trigger cell death directly by increasing mitochondrial permeability transition pore formation, leading to cytochrome c release and the activation of death inducing mitochondrial caspases [220, 221], even in the absence of programmed death receptor ligation. There is also some evidence that glutathione depletion is an indispensable step in the assembly of the apoptosome [222]. Decreased glutathione levels lead to the oxidation dependent dimerization and subsequent activation of Bax, and initiation of the intrinsic apoptotic pathway [223]. Glutathione loss leads to Bax translocation, from its bound state in the cytoplasm by 14-3-3 [224], into mitochondria leading to loss of mitochondrial membrane potential $\Delta\psi(m)$, dramatically increasing O&NS and leading to dysregulated calcium ion homeostasis and ultimately caspase-3/9 activation and cellular apoptosis [225–227].

The optimum functioning of the NMDA receptor is dependent on the redox environment, with prolonged glutathione depletion compromising synaptic plasticity, memory, and learning [228, 229]. Astrocyte glutathione depletion has serious consequences for the integrity and function of neurons [230]. Prolonged conditions of oxidative stress are deleterious in part by reducing the capacity of astrocytes to uptake glutamate [231]. Raised levels of extracellular glutamate are a common observation in many neurological diseases, increasing excitotoxicity or oxidative glutamate toxicity. This state is created by the oxidative stress related inhibition of cystine uptake by the x_c^- antiporter system leading to glutathione depletion [232]. Astrocyte glutathione release is well documented and is important to neuronal antioxidant defenses [233, 234]. As glutathione cannot be directly taken up by neurons, astrocyte released glutathione is coordinated with the upregulation of gamma-glutamyl transpeptidase, which cleaves glutathione to products which neurons can uptake, including cysteine [235, 236] which is imported by neuronal EAAT3 receptors [237].

Various states, including elevated O&NS, resulting in glutathione depletion have been shown to impair DNA methylation [238–240]. Therefore, elevated O&NS is considered to alter the methylation of DNA, which leads to changes in the gene expression [241]. There are a number of different overlapping mechanisms involved. ROS-induced DNA lesions, such as 8-OHdG, may inhibit the activity DNA methyltransferase at the adjacent cytosine base and subsequently prevent methylation at that site [242]. An unfixed 8-OHdG can lead to the introduction of a G-T transversion leading to a loss of CpG dinucleotides [243]. In a state of chronic O&NS, homeostatic mechanisms promote an increase in the resynthesis of glutathione in response to glutathione depletion via the methionine cycle. The synthesis of glutathione via the increase in the rate of one carbon metabolism requires *S*-adenosylmethionine as a substrate for synthesizing the homocysteine ultimately to be used for the glutathione synthesis. This leads to a diminished availability of *S*-adenosylmethionine for the purpose of DNA methylation [244]. Oxidative stress additionally increases the demand for SAME but concomitantly decreases its synthesis resulting in sub optimal methylation of DNA [245, 246].

Glutathione Depletion in Depression

Glutathione depletion and concomitant increase in O&NS, mitochondrial dysfunctions, and impaired DNA methylation play a role in the pathophysiology of neuroimmune disorders, including depression and ME/CFS. There are several reports of a dysregulated glutathione system with lowered glutathione levels and lowered levels of its related enzymes in individuals with depression and ME/CFS. Already in 1934, it was reported that glutathione may be lowered in the blood of schizophrenic patients [247].

Serum glutathione levels in depression have been directly measured. One study reports serum levels from individuals with recurrent depressive disorder. When compared to controls, those with depression had significantly lower glutathione levels. In parallel, decreased levels of glutathione peroxidase-1 are also reported. Interestingly, an increase in glutathione reductase was reported that may reflect the upregulation of glutathione cycling in response to depletion. Increased markers of oxidative stress were also observed, with increased MDA and hydrogen peroxide levels reported [248]. Maes et al. [249] reported lower glutathione peroxidase activity in whole blood samples taken from depressed patients compared to healthy controls. These authors reported a significant negative correlation between glutathione peroxidase and the severity of depression and the range and severity of autonomic symptoms. When comparing those considered to be having “active” depression to those in “remission”, Kaddurah-Daouk et al. [250] reported no difference in CSF glutathione levels either in remitted or currently depressed individuals, when compared to controls. However, there was

a trend that indicates that those with remitted depression had a lower level of CSF glutathione when compared to controls. This is reflected in the change in ratio between methionine and glutathione which is decreased in remitted depressed individuals when compared both the controls and also to those with current depression. It may be postulated that the 3-week wash-out criterion for inclusion into the study, in the currently depressed group, may account for some of the differences with the remitted group, where participants had to have at least 3 months without medication to be included [250].

In congruence with previous reports, serum superoxide dismutase and glutathione peroxidase levels are decreased and lipid peroxidation increased in those with depression compared to controls [251]. Moreover, when comparing those with first episode depression to those with chronic depression, superoxide dismutase levels were reduced in both groups, but further reduced in the recurrent group. This pattern was also seen in glutathione peroxidase and MDA levels with respective decreased and increased levels reported in the recurrent group compared to the first-episode group. In a study of matched controls, fibroblast cultures were investigated to compare oxidative stress and glutathione levels in those with major depression to healthy controls. Results showed increased protein carbonylation, while no changes in fibroblast glutathione levels were reported [252]. Similar to the work of Kaddurah-Douk et al. [250], these authors also found an increase in glutathione reductase. When investigating post-mortem tissue, studies have found decreased levels of both oxidized and reduced glutathione when compared to controls in the anterior cingulate cortex. Glutathione reductase and glutathione peroxidase levels were not found to be statistically altered; however, there was an indication that they were decreased in the depression group [253]. In post mortem prefrontal cortex, glutathione *S*-transferase levels (Mu isoform) were significantly lower in depressed and bipolar patients [254]. Reduced glutathione in postmortem brain has also been reported in autism [255].

The use of ^1H magnetic resonance spectroscopy in treatment-free patients demonstrated lower glutathione levels compared to nondepressed controls [256]. Do et al. [257] reported lowered glutathione measured both by spectroscopy and in CSF in patients with schizophrenia. There is a possible correlation between reduced glutathione and negative symptoms of schizophrenia, a signal that is reinforced by the results of clinical trials of glutathione replenishment strategies with *N*-acetyl cysteine, discussed later [258]. Biomarker studies such as those outlined above are further supported by genetic studies also showing perturbations in the glutathione pathway. In a study taken from one of the largest epidemiological samples available, the HUNT study, researchers have found increased polymorphisms in both the CGLM (three SNPs) and GCLC (nine SNPs) and a trinucleotide repeat [259]. These enzymes are responsible for the production of glutathione.


The pathophysiology of depression also appears to involve disturbed erythron and iron homeostasis likely as a result of inflammation and depleted glutathione. Changes in the erythron and iron metabolism are reported, such as decreased serum iron, number of erythrocytes, hemoglobin and hematocrit, and increased serum ferritin [260] and depleted polyunsaturated fatty acid levels in the erythrocyte membrane [261, 262].

Erythrocytes play a major role as free radical scavengers [263]. They are continuously exposed to ROS in the systemic circulation and the autooxidation of hemoglobin in the cytosol [264]. Erythrocytes are at high risk of oxidative stress due to high ferrous iron load largely stemming from ferryl-hemoglobin formation and hydroxyl radical production via the Fenton reaction between H_2O_2 and Fe^{2+} [265]. The plasma membranes of erythrocytes are very sensitive to damage by oxidative stress because of the very high percentage of unsaturated lipids which underlie their considerable flexibility [263]. Progressively increasing oxidative stress causes changes in the primary structure and functions of hemoglobin, which may lead to hemolysis [266].

Glutathione is the primary defense against oxidative stress in erythrocytes, and adequate levels are essential for maintaining the natural conformation of hemoglobin [266]. Optimum erythrocyte glutathione levels are therefore critical in minimizing the damaging effects of ROS and autooxidation of hemoglobin in the cytosol [265]. In conditions of chronic oxidative stress, GSSH is expelled from the cell by virtue of membrane transporters and increased membrane permeability [2, 266]. Hence in this context, glutathione is quite literally a life-enabling molecule. A visual representation of the relationship between iron, hemoglobin, and glutathione in erythrocytes may be viewed in Fig. 3. Given the role of erythrocytes as ROS scavengers, depleted numbers of these cells could contribute to the elevated levels of ROS seen in major depression [263].

Glutathione Depletion in ME/CFS

The plethora of different unvalidated diagnostic criteria for ME and CFS makes comparison between research findings produced by different authors sometimes difficult [267]. Using proton NMR spectroscopy, Shungu et al. [268] reported depleted levels of glutathione in the CSF and cerebral cortex of people with ME/CFS which correlated inversely with several measures of physical function. This was in contrast with earlier work which did not detect any abnormalities in the brain or CFS of patients albeit using inferior technology [269]. These authors cited the small sample size as the likely reason that the depletion in glutathione did not reach statistical significance. Kennedy et al. [270] reported low glutathione levels in erythrocytes in patients with ME/CFS echoing an earlier finding [271]. Increased glutathione peroxidase activity in



Abbreviations.

6PG: 6-Phosphogluconic acid.
G6P: Glucose 6-phosphate.
G6PD: Glucose-6-phosphate dehydrogenase
GSH: glutathione.
GSSG: oxidized glutathione.
 H_2O : water
 H_2O_2 : hydrogen peroxide.

$\text{Hb}(\text{Fe}^{2+})$: hemoglobin.
 $\text{MetHb}(\text{Fe}^{3+})$: methemoglobin.
NADP: nicotinamide adenine dinucleotide phosphate.
NADPH: nicotinamide adenine dinucleotide phosphate-oxidase.
ROS: reactive oxygen species.

Fig. 3 Methemoglobin (MetHb) is a conformationally abnormal hemoglobin (Hb) continually produced in the body where the iron molecule is in the higher oxidation ferric state, rather than the normal ferrous state, which inhibits its oxygen-binding properties. Red blood cells can combat the development of oxidative stress, which would otherwise lead to inactivation of hemoglobin and disruption of red blood cell membranes by a number of mechanisms. The most important is reliant on nicotinamide adenine dinucleotide phosphate (NADPH), which is produced by the pathway often called the hexose monophosphate shunt. This NADPH reduces oxidized glutathione to glutathione (GSH) maintaining high levels of GSH even when ROS concentrations are high. GSH acts as an essential cofactor for glutathione peroxidase, resulting in the reduction or elimination of ROS and minimizing the formation of methemoglobin

skeletal muscle extracted from patients with this illness has also been reported in people carrying the same diagnosis [272]. Logan and Wong [273] reported an improvement in disability levels in patients with ME/CFS following supplementation with glutathione or *N*-acetyl cysteine. Other workers have suggested the presence of low glutathione in patients with ME/CFS, and it has been suggested that low glutathione and the consequent increase in blood-brain barrier permeability may be a critical element in the etiopathology of ME/CFS [274, 275]. A number of authors have reported depleted glutathione levels in CFS and an improvement in fatigue following supplementation with ginseng or moxibustion [276, 277]. Several research teams using rat models of ME/CFS have reported depleted levels of glutathione peroxidase in their animals [278, 279]. This may complement the finding reported by Maes et al. [249] who found that serum glutathione peroxidase levels were not altered in people with

ME/CFS. Several authors have reported findings of low glutathione in studies using mouse models of ME/CFS where fatigue has been induced mechanically or by immunological means and relieved by the use of certain dietary supplements or acupuncture [280–285].

Implication of the Glutathione System in the Pathophysiology of Depression and ME/CFS

Recently, we have reviewed that depression and ME/CFS are accompanied by similarly dysregulated immune-inflammatory and O&NS pathways, including increased levels of proinflammatory cytokines, intracellular signaling pathways, oxidative damage of fatty acids and lipids (as indicated by increased 4-HNE and MDA), oxidative damage to DNA (as demonstrated by increased 8-OHdG levels), autoimmune reactions directed towards neoepitopes produced by the corrosive actions of ROS on fatty acids located in cellular membranes), and autoimmune reactions against oxidative-specific epitopes and nitrosatively modified proteins [249, 286]. We also reviewed that mitochondrial dysfunctions are heavily involved in the pathophysiology of these three disorders, including lowered ATP production, impaired oxidative phosphorylation, and dysfunctions in the mitochondrial respiratory chain [259, 286, 287]. Epigenetic changes are now acknowledged to take part in the pathophysiology of depression and a chronic fatigue-related condition, such as fibromyalgia [288–290]. Induction of apoptotic pathways and alterations in glutamate metabolism are observed in depression and ME/CFS [72, 276, 288, 291–293]. It is therefore not difficult to appreciate that depletion of glutathione and its related enzymes may contribute to the abovementioned pathways in depression and ME/CFS. Treatments targeting the glutathione system in depression and ME/CFS further underscore the important role of glutathione and related enzymes in the pathophysiology of these neuroimmune disorders (see “Treatments targeting the glutathione system” section).

Glutathione Depletion in Parkinson’s Disease

The interplay between depleted levels of glutathione, mitochondrial dysfunction, elevated oxidative stress, and apoptosis is also evidenced in the pathophysiology of Parkinson’s disease [294]. Depletion of glutathione (GSH + GSSH) in the substantia nigra of the brain is an early biochemical occurrence in the development of this illness and is detected prior to the inhibition of complex I activity [295]. Complex I deficiency is seen in the substantia nigra and the frontal cortex in patients with Parkinson’s disease, but it is also evident in peripheral mononuclear blood cells, platelets, and skeletal muscle, indicating that impaired mitochondrial complex I activity is a global phenomenon in Parkinson’s disease

[294]. Glutathione depletion leads to impaired development of iron sulfur proteins and leads to iron buildup in cells [296]. Hence, glutathione depletion is likely driver of the elevated iron levels seen in the substantia nigra in Parkinson’s disease patients [297]. Impaired iron homeostasis is a source of cellular toxicity via the generation of superoxide and hydroxyl radicals via the Fenton reaction, and these species are the effector molecules by which excess iron levels contribute to the pathogenesis of this disease [298, 299]. In these conditions, the damage caused by hydroxyl radicals is exacerbated as the loss of glutathione inactivates the main mechanism enabling their clearance from the cell [2]. While some authors argue that inhibition of mitochondrial complex I and subsequent mitochondrial dysfunction in Parkinson disease substantia nigra cells is mediated by glutathionylation, the loss of GSH and GSSH argues for inhibition by nitric oxide in this case and not GSSH [297, 295]. As previously discussed, glutathione biosynthesis is an energy-dependent process [2], and mitochondrial dysfunction significantly depletes glutathione production thereby further exacerbating oxidative damage which further impairs electron transport chain activity which in turn leads to elevated levels of ROS and RNS [300].

In the case of Parkinson’s disease, mitochondrial dysfunction driven by spiraling increases in O&NS and glutathione depletion may become self-sustaining via a feedback loop leading to further compromised electron transport chain inhibition at complex III, exacerbated macromolecule damage, failure of the ubiquitin proteome system, and, ultimately, neuronal apoptosis involving all the mechanisms discussed above [294].

Treatments Targeting the Glutathione System

Glutathione

Glutathione supplementation would obviously be an attractive option, but its absorption and effectiveness in blood is low [301]. Oral glutathione is readily hydrolyzed by dipeptidases in the gastrointestinal tract, and, hence, this form of administration is not a suitable vehicle for raising glutathione levels in cells. Glutathione administered as an infusion also suffers from serious defects. It is rapidly eliminated by gamma-glutamyl transpeptidase in the circulation and has a fleetingly short half life of 7 to 10 min [302]. Glutathione supplementation in any shape or form cannot replenish diminished levels of glutathione in the central nervous system as the molecule does not cross the blood-brain barrier to any significant extent [303, 304]. One study demonstrated that only 0.5 % of glutathione injected into the carotid space of rats could later be detected in brain tissue [302].

N-Acetyl Cysteine

Administration of the cysteine prodrug *N*-acetyl cysteine restores intracellular glutathione levels. *N*-acetyl cysteine increases glutathione levels in vivo and vitro [305–307]. *N*-acetyl cysteine is a well-tolerated treatment for glutathione deficiency with an excellent safety record and has been used successfully to increase glutathione levels in a wide range of metabolic and neuroimmune illnesses as well as in infections, including HIV. In excess of 65 % of 46 placebo-controlled clinical trials with *N*-acetyl cysteine have reported benefits measured empirically or by self-reported improvement in quality of life parameters [308]. For a detailed review of its chemistry and biological activity, see Samuni et al. [309].

There is evidence that *N*-acetyl cysteine may boost immune function directly [310] and that *N*-acetyl cysteine possesses heavy metal-chelating capacity [311]. The studies report a range of results which appear to vary in accordance with the dose and duration of *N*-acetyl cysteine treatment. De Quay et al. [312] reported that markedly depleted glutathione and cysteine levels in plasma and T-lymphocytes normalized following a single dose of *N*-acetyl cysteine at 30 mg/kg, whereas no changes were reported using 800 mg a day [313]. Herzenberg et al. [314] reported that in HIV patients *N*-acetyl cysteine at a maximum dose of 8 g a day for 8 weeks increased glutathione levels by 113 % and that the *N*-acetyl cysteine group had a higher chance of survival after 24 months than the control group. Chen et al. [315] noted that *N*-acetyl cysteine at a concentration of 10^{-4} mol/L significantly increased glutathione levels and the GSH/GSSG ratio in HIV positive patients whereas *N*-acetyl cysteine at 10^{-7} mol/L did not.

N-acetyl cysteine has been used with some efficacy as an adjunctive treatment for depression. Randomized controlled trials of *N*-acetyl cysteine have shown benefit following 6 months of treatment at 2,000 mg/day in people with bipolar disorder [316]. When specifically investigating depression, the researchers have shown that those who were currently experiencing a depressive episode at the commencement of the study had significant reductions in depressive symptoms at the 6-month timepoint [317]. In a larger, maintenance designed trial, participants were reported to have large decreases in depression severity scores following 8 weeks of open-label *N*-acetyl cysteine treatment [318]. Following this, participants were randomized to continued *N*-acetyl cysteine treatment or placebo. Results showed no statistical differences between *N*-acetyl cysteine and placebo groups at the 6-month time point [318]. In a RCT investigating 2,000 mg/day of NAC (compared with placebo and in addition to treatment as usual) for major depressive disorder, results showed no improvement at the 12-week treatment cutoff between *N*-acetyl cysteine and placebo groups. However, when exploring the effects of including the postdiscontinuation visit, depressive scores were reduced in the *N*-acetyl cysteine group. There was a

suggestion of efficacy in individuals with more severe depression, defined as a Montgomery Asberg Depression Rating score above 25, but with no efficacy evident below that cutoff. Other functional outcomes were found to be significant at week 12. Taken together, these data provides some support for the use of *N*-acetyl cysteine as an adjunctive antidepressant (Berk et al., in press).

In a study of *N*-acetyl cysteine in schizophrenia, beneficial effects were seen across symptom domains including akathisia, but with highest effect sizes in negative symptoms [316, 318]. This pattern mirrors the spectroscopy finding that lowered glutathione appears linked to negative symptoms of schizophrenia. This finding has recently been replicated [319]. *N*-acetyl cysteine has also shown efficacy in two studies in autism, particularly in symptoms of irritability [320].

Folate, Lipoic Acid, and Coenzyme Q10

Oral folate supplementation is a proven approach for increasing the levels of glutathione [321], glutathione *S*-transferase, glutathione peroxidase, and glutathione reductase [322]. Methylfolate is the only form of folate capable of crossing the blood-brain barrier due to the presence of a methylfolate active transport system within that structure [323, 324].

A dose of 15 mg of methylfolate a day has proven to be an effective treatment for people with depression who are resistant to antidepressants [323]. Folate supplementation is an effective adjuvant to SSRIs in treatment-resistant depression even when folate levels are normal [325, 326]. The lowest effective dose of methylfolate capable of augmenting antidepressants is 7.5 mg, which is approximately equivalent to 52 mg of folic acid [327]. By binding to folate transport receptors, methylfolate precursors may compete with folate-derived methylfolate for uptake into the central nervous system. This obviously limits the amount of methylfolate that can enter the brain [328]. Thus, high doses of methylfolate which do not involve the synthesis of precursor molecules can provide significantly more active methylfolate than high doses of folic acid [328].

Alpha-lipoic acid is a mitochondrial nutrient that improves age-associated mitochondrial and cognitive dysfunction, which is at least partly mediated by its antioxidant effects [329]. In non-alcoholic steatosis, alpha-lipoic acid affords protection by doubling glutathione peroxidase levels with associated increases in sirtuins, further enhancing mitochondrial functioning [330].

Coenzyme Q10 is a robust antioxidant and mitochondria regulator that affords protection against O&NS [331]. Coenzyme Q10 is significantly decreased in depression and ME/CFS and in many other conditions, where it often associates with fatigue [332, 286]. Coenzyme Q10, in a concentration-dependent manner, prevents stress-induced decreases in glutathione peroxidase and glutathione [333]. Coenzyme Q10

shows possible benefits on depressive symptoms in an elderly depressed population [334].

Supplementation with garlic extracts from fresh raw garlic, aged black garlic, and aged red garlic could be regarded as a protection against the loss of glutathione as the extracts reduce ROS production and increase glutathione levels [335]. Exposure to dietary acrylamide is very frequent during lifetime, and there is evidence that acrylamide reduces glutathione concentrations. The effect is counteracted by procyanidin B₂ and cacao polyphenolic extract [336]. An important strategy to increase glutathione is the use of glutathione esters as the esters can restore mitochondrial levels of glutathione. For example, central administration with one of these glutathione esters, monoethyl (GEE), results in increased glutathione, providing neuroprotection against O&NS or mitochondrial impairment.

Treatments Targeting Nrf-2

Nrf-2 is redox-sensitive and orchestrates cellular cytoprotective responses to increased oxidative stress by regulating cellular antioxidant defenses [337]. It moderates a plethora of genes by interacting with the antioxidant response element (ARE) [338]. Nrf-2 is normally confined to the cytoplasm by being bound to an inhibitor molecule, i.e., Keap-1 [337]. The latter molecule likely acts as a redox sensor [337] and oxidative stress leads to the dissociation of the molecular complex releasing Nrf-2 which consequently translocates to the nucleus [339]. The dissociation of the Nrf-2/Keap-1 complex largely follows the modification of Keap-1 cysteine residues via direct oxidation or conjugation [339, 340]. Numerous studies have demonstrated that Nrf-2 is critical for the activation of the cellular glutathione system and maintaining the redox state [341]. Nrf-2 regulates the de novo glutathione synthesis, glutathione peroxidase (GPX2), glutathione *S*-transferases, glutathione reductase, the synthesis of enzymes that mediate glutathione synthesis, i.e., glutathione cysteine ligase modifier subunit and glutathione cysteine ligase catalytic subunit, and the x_c⁻ cysteine/glutamate antiporter system and consequently determines cellular glutathione levels [341]. For example, Nrf-2 activation restores glutathione levels in neutrophils taken from patients with chronic periodontitis [342, 343]. In the next sections, we discuss different treatment modalities that may upregulate Nrf-2.

Hyperbaric Oxygen Therapy

The Nrf-2-mediated oxidative stress response is activated by hyperbaric oxygen therapy (HBOT) [344]. HBOT induces significant changes in Nrf-2-induced antioxidant pathways, while only minimal changes were observed following treatment with 100 % O₂ [345]. At normal pressure, HBOT does not appear to increase the transcription of Nrf-2, but likely acts to free Nrf-2 and enable its translocation to the nucleus [344,

346]. A number of studies report increased glutathione following HBOT [347–349]. HBOT has also been shown to provoke transcription of the cytoprotective protein heme oxygenase-1, another mechanism by which HBOT expression may protect cells against the corrosive effects of O&NS [350–352].

Phytochemicals

Many phytochemicals upregulate the Nrf-2/Keap1 system [353] and have been demonstrated to upregulate glutathione levels [354, 355]. Curcumin, for example, upregulates the transcription of genes coding for antioxidant and phase II enzymes [356–358]. This induced transcription is modulated via ROS-induced activation of Nrf-2, which proceeds through phosphorylation of MAP kinases and PKC [359, 360]. The efficacy of curcumin as a treatment has been demonstrated in a number of studies involving animal models of depression [361–363]. In a recent randomized trial, curcumin, 1,000 mg/day, was shown to be as effective as fluoxetine, 20 mg/day [361]. Gupta et al. [363] demonstrated the efficacy of curcumin in ameliorating fatigue and oxidative stress in mice with immunologically induced fatigue, which is perhaps the closest animal model of ME/CFS.

Carnosol [364], resveratrol [365], and cinnamaldehyde [366] stimulate antioxidant enzymes via the same mechanism. Resveratrol has demonstrated efficacy in mouse models of ME/CFS at least as far as reducing hippocampal atrophy is concerned [367]. However, as with direct glutathione intake, the efficacy of curcumin and resveratrol are limited by their metabolism in the gastrointestinal tract.

Green tea's epigallocatechin gallate (EGCG) is another compound with ubiquitous benefits, including affording protection against depression [368]. This is mediated partly via EGCG improving mitochondrial functioning, but also by EGCG increasing Nrf-2 and endogenous antioxidants, including glutathione and glutathione peroxidase [369]. In addition, glutathione levels are dose-dependently increased after use of sulforaphane, followed by lipoic acid, resveratrol, and *Polygonum multiflorum*. All four compounds potentially induce glutathione levels via activation of the Nrf2-ARE pathway [370]. As such, the efficacy of many phytochemicals across a range of conditions is intimately associated with the regulation and availability of glutathione.

Dimethyl Fumarate

Dimethyl fumarate is approved as a treatment for psoriasis in some European countries. Dimethyl fumarate has antiproliferative effects on lymphocytes, diminishes inflammatory gene expression (e.g., microglial and astroglial IL-1, IL-6 and TNFα), increases anti-inflammatory gene expression (e.g., IL-10), suppresses NF-κB nuclear transport and dependent

transcription (in astroglia) and consequently reduces NO synthase gene expression, and has antioxidative and neuroprotective effects [371]. Dimethyl fumarate activates the Nrf-2 pathway leading to a significant stimulation of the glutathione system [371, 372]. Thus, in astrocytes, dimethyl fumarate increases Nrf-2 levels (after an initial decrease), reverses LPS-induced decreases in mRNA of glutathione reductase, c-glutamylcysteine and glutathione synthetase, reduces nitrite levels, and increases mRNA of the anti-inflammatory heme oxygenase-1 [371]. Dimethyl fumarate is also used as a treatment of multiple sclerosis following the demonstration of the disease-modifying ability in those patients and in experimental autoimmune encephalomyelitis [373, 374]. A phase 2 trial with dimethyl fumarate in relapsing-remitting multiple sclerosis showed significant reductions in new gadolinium-enhancing lesions [375].

Psychiatric Medications

It should be noted that antidepressants, mood stabilizers, and many antipsychotic medications increase glutathione and Nrf-2 levels [338]. As such, many of their multitargeted effects, which seem necessary for their efficacy [293], may be mediated via the important cellular and intercellular functions of glutathione and its interactions with, and regulation of, factors known to be altered in psychosis and mood disorders [376].

Conclusions

The glutathione-related redox state of cells plays an important role in the regulation of proinflammatory cytokines, including TNF α , IL-1 β , and IL-6, and the activity of intracellular signaling pathways. Glutathione depletion enhances the transcription and damaging effects of these cytokines and predisposes to a pro-inflammatory environment. Glutathione also has antiviral effects and can inhibit the replication of many viruses; hence, depletion of glutathione can have serious consequences and compromise an effective immune response against invading viruses. Glutathione modulates the function of T cells and NKCs with depletion in glutathione levels leading to compromised NK function, T cell activation, and proliferation and a predisposition to a Th2-biased immune response.

Glutathione is a crucial component of cellular antioxidant defenses and hence a vital player in detoxification of ROS and RNS and their toxic metabolites such as lipid peroxides. The glutathione system as a whole enables the detoxification of xenobiotics and polymorphisms in glutathione enzymes and is a major source of pathology and drug resistance. *S*-Glutathionylation, i.e., the posttranscriptional addition of glutathione to protein cysteine, modifies the activity of many proteins include kinases and other cellular signaling proteins and proteins involved in energy production and calcium

homeostasis and inhibits the activity of many important enzymes such as phosphofructokinase and creatine kinase. The activities of a wide range of other proteins may be up- or downregulated by *S*-glutathionylation.

The GSH/GSSH ratio and the level of glutathionylation regulate the mechanisms enabling cellular proliferation, DNA synthesis and repair, and division and apoptosis with a depletion of GSH leading to impaired cellular division and proliferation and increased levels of apoptosis. Mitochondrial survival and function is dependent on the glutathione system. Glutathione depletion and increased glutathionylation leads to inhibition of the electron transport chain diminishing ATP production increasing the production of ROS and inhibiting the *de novo* synthesis of glutathione from its amino acid precursors. This situation ultimately leads to loss of mitochondrial membrane potential, the release of cytochrome c and mitochondrial apoptosis.

Glutathione has important functions in the brain as an antioxidant and neuromodulator and promoter of neuronal survival. Glutathione synthesis acts as a neuromodulator of the glutamate ionotropic receptors, interacts with NMDA receptors, and protects against glutamate excitotoxicity. The optimum functioning of the NMDA receptor is dependent on the redox environment, with prolonged glutathione depletion compromising synaptic plasticity, memory, and learning. Glutathione may also be a neurotransmitter in its own right and its depletion impairs the activity of the methionine cycle leading to impaired DNA methylation and epigenetic regulation of gene expression.

Lowered activity of the glutathione system is observed in neuroimmune disorders, including depression, ME/CFS, and Parkinson's disease. The abovementioned functions of the glutathione system and the consequences of glutathione depletion explain that lowered activity of the glutathione system plays a role in the immune-inflammatory and O&NS pathophysiology of these diseases. A number of approaches show promise in raising glutathione levels and combating the elevated levels of O&NS which has a causative role in the development of many neuroimmune diseases. Although direct glutathione supplementation appears to be ineffective, the use of *N*-acetyl cysteine, phytochemicals, HBOT, and dimethyl fumarate shows considerable promise.

Funding No specific funding was obtained for this specific review.

Conflict of Interests The authors declare that they have no competing interests.

References

1. Mari M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC (2009) Mitochondrial glutathione, a key survival antioxidant. *Antioxid Redox Signal* 11:2685–700, PMID: 19558212

2. Lushchak VI (2012) Glutathione homeostasis and functions: potential targets for medical interventions. *J Amino Acids* 2012:736837, PMID: 22500213
3. Haddad JJ, Harb HL (2005) L-Gamma-glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)? *Mol Immunol* 42: 987–1014, PMID: 15829290
4. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 39:44–84, PMID: 16978905
5. Oja SS, Jenei Z, Janáky R, Saransaari P, Varga V (1994) Thiol reagents and brain glutamate receptors. *Proc West Pharmacol Soc* 37:59–62
6. Makarov P, Kropf S, Wiswedel I, Augustin W, Schild L (2006) Consumption of redox energy by glutathione metabolism contributes to hypoxia/reoxygenation-induced injury in astrocytes. *Mol Cell Biochem* 286:95–101, PMID: 16583144
7. Halliwell B, Gutteridge JMC (1989) *Free radicals in biology and medicine*. Clarendon Press, Oxford
8. Cooper AJ, Pulsinelli WA, Duffy TE (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. *J Neurochem* 35:1242–5, PMID: 7452315
9. Kumar C, Igbaria A, D'Autreaux B, Planson AG, Junot C, Godat E, Bachhawat AK, Delaunay-Moisan A, Toledano MB (2011) Glutathione revisited: a vital function in iron metabolism and ancillary role in thiol-redox control. *EMBO J* 30:2044–56. doi:10.1038/emboj.2011.105, PMID: 21478822
10. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. *Antioxid Redox Signal* 10:1343–74. doi:10.1089/ars.2007.1957, PMID: 18522489
11. Sheehan D, Meade G, Foley VM, Dowd CA (2001) Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochem J* 360:1–16
12. Zhang H, Forman HJ (2009) Redox regulation of gamma-glutamyl transpeptidase. *Am J Respir Cell Mol Biol* 41:509–15
13. Cooper AJL, Hanigan MH (2010) 4.17—Enzymes involved in processing glutathione conjugates. In: *Comprehensive toxicology* 4:323–66. 2nd edition
14. McIlwain CC, Townsend DM, Tew KD (2006) Glutathione *S*-transferase polymorphisms: cancer incidence and therapy. *Oncogene* 25:1639–48, PMID: 16550164
15. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, Green B, Lang NP, Kadlubar FF (2001) Effect of polymorphism in the human glutathione *S*-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. *Pharmacogenetics* 11:663–9, PMID: 11692074
16. Fernandes AP, Holmgren A (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. *Antioxid Redox Signal* 6:63–74, PMID: 14713336
17. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. *Nutrients* 4:1399–440. doi:10.3390/nu4101399, PMID: 23201762
18. Peltoniemi M, Kaarteenaho-Wiik R, Säily M, Sormunen R, Pääkkö P, Holmgren A, Soini Y, Kinnula VL (2004) Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. *Hum Pathol* 35:1000–7, PMID: 15297967
19. Pai HV, Starke DW, Lesnefsky EJ, Hoppel CL, Mieyal JJ (2007) What is the functional significance of the unique location of glutaredoxin 1 (GRx1) in the intermembrane space of mitochondria? *Antioxid Redox Signal* 9:2027–33, PMID: 17845131
20. Hinchman CA, Ballatori N (1994) Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process. *J Toxicol Environ Health* 41:387–409
21. Kalyanaraman B, Karoui H, Singh RJ, Felix CC (1996) Detection of thiyl radical adducts formed during hydroxyl radical- and peroxynitrite-mediated oxidation of thiols—a high resolution ESR spin-trapping study at Q-band (35 Ghz). *Anal Biochem* 241:75–81
22. Gardner JM, Aust SD (2009) Quantification of hydroxyl radical produced during phacoemulsification. *J Cataract Refract Surg* 35: 2149–53, PMID: 19969222
23. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA (2009) Nitric oxide in cell survival: a Janus molecule. *Antioxid Redox Signal* 11:2717–39
24. Siems W, Crifo C, Capuozzo E, Uchida K, Grune T, Salerno C (2010) Metabolism of 4-hydroxy-2-nonenal in human polymorphonuclear leukocytes. *Arch Biochem Biophys* 503:248–52
25. Zhu X, Gallogly MM, Mieyal JJ, Anderson VE, Sayre LM (2009) Covalent cross-linking of glutathione and carnosine to proteins by 4-oxo-2-nonenal. *Chem Res Toxicol* 22:1050–9
26. Jones DP, Park Y, Gletsu-Miller N, Liang Y, Yu T, Accardi CJ, Ziegler TR (2011) Dietary sulfur amino acid effects on fasting plasma cysteine/cystine redox potential in humans. *Nutrition* 27: 199–205, PMID: 20471805
27. Jones DP (2002) Redox potential of GSH/GSSG couple: assay and biological significance. *Methods Enzymol* 348:93–112
28. Holmgren A, Sengupta R (2010) The use of thiols by ribonucleotide reductase. *Free Radical Biol Med* 49:1617–28
29. Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC (2003) Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. *Acta Biochim Pol* 50:319–36
30. Zhang D, Lu H, Li J, Shi X, Huang C (2006) Essential roles of ERKs and p38K in up-regulation of GST A1 expression by Maotai content in human hepatoma cell line Hep3B. *Mol Cell Biochem* 293:161–71, PMID: 16786188
31. Yang Y, Cheng JZ, Singhal SS, Saini M, Pandya U, Awasthi S, Awasthi YC (2001) Role of glutathione *S*-transferases in protection against lipid peroxidation. Overexpression of hGSTA2-2 in K562 cells protects against hydrogen peroxide-induced apoptosis and inhibits JNK and caspase 3 activation. *J Biol Chem* 276:19220–30, PMID: 11279091
32. Sakai M, Muramatsu M (2007) Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. *Biochem Biophys Res Commun* 357:575–8, PMID: 17434454
33. Li Y, Cohenford MA, Dutta U, Dain JA (2008) The structural modification of DNA nucleosides by nonenzymatic glycation: an in vitro study based on the reactions of glyoxal and methylglyoxal with 2'-deoxyguanosine. *Anal Bioanal Chem* 390:679–88
34. Karlson EW, Watts J, Signorovitch J, Bonetti M, Wright E, Cooper GS, McAlindon TE, Costenbader KH, Massarotti EM, Fitzgerald LM, Jajoo R, Husni ME, Fossel AH, Pankey H, Ding WZ, Knorr R, Condon S, Fraser PA (2007) Effect of glutathione *S*-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury Lupus Project. *Arthritis Rheum* 56:244–54, PMID: 17195228
35. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossu P, Caltagirone C, Federici G, Spalletta G, Bernardini S (2011) Genetic polymorphisms of glutathione *S*-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. *Psychiatry Res* 187:454–6
36. Nafissi S, Saadat I, Saadat M (2011) Genetic polymorphisms of glutathione *S*-transferase Z1 in an Iranian population. *Mol Biol Rep* 38:3391–4. doi:10.1007/s11033-010-0447-x, PMID: 21107728
37. Williams TA, Mars AE, Buyske SG, Stenroos ES, Wang R, Fatura-Santiago MF, Lambert GH, Johnson WG (2007) Risk of autistic disorder in affected offspring of mothers with a glutathione *S*-

- transferase P1 haplotype. *Arch Pediatr Adolesc Med* 161:356–61, PMID: 17404132
38. Rezaei Z, Saadat I, Saadat M (2012) Association between three genetic polymorphisms of glutathione *S*-transferase Z1 (GSTZ1) and susceptibility to bipolar disorder. *Psychiatry Res* 30:166–8. doi: [10.1016/j.psychres.2011.09.002](https://doi.org/10.1016/j.psychres.2011.09.002), PMID: 22374552
 39. Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician* 76:391–6
 40. Wu Y, Zhang X, Bardag-Gorce F, Robel RC, Aguilo J, Chen L, Zeng Y, Hwang K, French SW, Lu SC, Wan YJ (2004) Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. *Mol Pharmacol* 65:550–7, PMID: 14978233
 41. Coles BF, Kadlubar FF (2003) Detoxification of electrophilic compounds by glutathione *S*-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? *Biofactors* 17:115–30
 42. Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. *Annu Rev Pharmacol Toxicol* 45:51–88
 43. Huang KP, Huang FL (2002) Glutathionylation of proteins by glutathione disulfide *S*-oxide. *Biochem Pharmacol* 64:1049–56, PMID: 12213604
 44. Poole LB, Karplus PA, Claiborne A (2004) Protein sulfenic acids in redox signaling. *Annu Rev Pharmacol Toxicol* 44:325–47, PMID: 14744249
 45. Holmgren A, Lu J (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. *Biochem Biophys Res Commun* 396:120–4
 46. Townsend DM (2008) *S*-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. *Mol Interv* 7:313–24
 47. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD (2008) Molecular mechanisms and clinical implications of reversible protein *S*-glutathionylation. *Antioxid Redox Signal* 10:1941–88
 48. Manevich Y, Feinstein SI, Fisher AB (2004) Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. *Proc Natl Acad Sci U S A* 101:3780–5, PMID: 15004285
 49. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD (2009) Novel role for glutathione *S*-transferase pi Regulator of protein *S*-glutathionylation following oxidative and nitrosative stress. *J Biol Chem* 284:436–45. doi:[10.1074/jbc.M805586200](https://doi.org/10.1074/jbc.M805586200), PMID: 18990698
 50. Mieyal JJ, Starke DW, Gravina SA, Hocevar BA (1991) Thiolttransferase in human red blood cells: kinetics and equilibrium. *Biochemistry* 30:8883–91
 51. Lind C, Gerdes R, Schuppe-Koistinen I, Cotgreave IA (1998) Studies on the mechanism of oxidative modification of human glyceraldehyde-3-phosphate dehydrogenase by glutathione: catalysis by glutaredoxin. *Biochem Biophys Res Commun* 247:481–6, PMID: 9642155
 52. Reddy S, Jones AD, Cross CE, Wong PS, Van Der Vliet A (2000) Inactivation of creatine kinase by *S*-glutathionylation of the active-site cysteine residue. *Biochem J* 347:821–7, PMID: 10769188
 53. Pineda-Molina E, Klatt P, Vázquez J, Marina A, García de Lacoba M, Pérez-Sala D, Lamas S (2001) Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. *Biochemistry* 40:14134–42, PMID: 11714266
 54. Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, Heintz NH, Heim J, Ho YS, Matthews DE, Wouters EF, Janssen-Heininger YM (2006) Dynamic redox control of NF-kappaB through glutaredoxin-regulated *S*-glutathionylation of inhibitory kappaB kinase beta. *Proc Natl Acad Sci U S A* 103:13086–91, PMID: 16916935
 55. Rao RK, Clayton LW (2002) Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. *Biochem Biophys Res Commun* 293:610–6
 56. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP (2003) Reversible glutathionylation of complex I increases mitochondrial superoxide formation. *J Biol Chem* 278:19603–10
 57. Chen YR, Chen CL, Pfeiffer DR, Zweier JL (2007) Mitochondrial complex II in the post-ischemic heart: oxidative injury and the role of protein *S*-glutathionylation. *J Biol Chem* 282:32640–54
 58. Humphries KM, Juliano C, Taylor SS (2002) Regulation of cAMP-dependent protein kinase activity by glutathionylation. *J Biol Chem* 277:43505–11
 59. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein *S*-glutathionylation via disulfide *S*-oxide formation. *J Biol Chem* 276:29596–602
 60. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmons M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vanekerckhove J, Gianazza E, Ghezzi P (2002) Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. *Proc Natl Acad Sci U S A* 99:3505–10
 61. Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and *S*-nitrosothiols. *Biochim Biophys Acta* 1658:44–49, PMID: 15282173
 62. Martínez-Ruiz A, Lamas S (2004) *S*-nitrosylation: a potential new paradigm in signal transduction. *Cardiovasc Res* 62:43–52, PMID: 15023551
 63. Jourdain D, Jourdain FL, Feelisch M (2003) Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism. *J Biol Chem* 278:15720–6
 64. Mannick JB, Schonhoff CM (2002) Nitrosylation: the next phosphorylation? *Arch Biochem Biophys* 408:1–6, PMID: 12485597
 65. Hogg N (2002) The biochemistry and physiology of *S*-nitrosothiols. *Ann Rev Pharmacol Toxicol* 42:585–600, PMID: 11807184
 66. Martínez-Ruiz A, Lamas S (2007) Signalling by NO-induced protein *S*-nitrosylation and *S*-glutathionylation: convergences and divergences. *Cardiovasc Res* 75:220–8, PMID: 17451659
 67. Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I (2004) *S*-glutathionylation: from redox regulation of protein functions to human diseases. *J Cell Mol Med* 8:201–12, PMID: 15256068
 68. Aracena-Parks P, Goonasekera SA, Gilman C, Dirksen RT, Hidalgo C, Hamilton SL (2006) Identification of cysteines involved in *S*-nitrosylation, *S*-glutathionylation, and oxidation to disulfides in RyR1. *J Biol Chem* 281:40354
 69. Yang Y, Loscalzo J (2005) *S*-nitrosoprotein formation and localization in endothelial cells. *Proc Natl Acad Sci U S A* 102:117–22, PMID: 15618409
 70. Qanungo S, Starke DW, Pai HV, Mieyal JJ, Nieminen AL (2007) Glutathione supplementation potentiates hypoxic apoptosis by *S*-glutathionylation of p65-NFkappaB. *J Biol Chem* 282:18427–36
 71. Pineda-Molina E, Klatt P, Vázquez J, Marina A, García DL (2001) Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. *Biochemistry* 40:14134–42
 72. Morris G, Maes M (2013) A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome. *Metab Brain Dis* 28:523–40. doi:[10.1007/s11011-012-9324-8](https://doi.org/10.1007/s11011-012-9324-8), PMID: 22718491
 73. Morris G, Maes M (2012) Increased nuclear factor-κB and loss of p53 are key mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Med Hypotheses* 79:607–13. doi:[10.1016/j.mehy.2012.07.034](https://doi.org/10.1016/j.mehy.2012.07.034), PMID: 22951418
 74. Marshall HE, Stamler JS (2001) Inhibition of NF-kappa B by *S*-nitrosylation. *Biochemistry* 40:1688–93, PMID: 11327828

75. Marshall HE, Hess DT, Stamler JS (2004) S-nitrosylation: physiological regulation of NF-kappaB. *Proc Natl Acad Sci U S A* 101: 8841–2, PMID: 15187230
76. Into T, Inomata M, Nakashima M, Shibata K, Häcker H, Matsushita K (2008) Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses. *Mol Cell Biol* 28:1338–47, PMID: 18086890
77. Haddad JJ (2002) The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK(p38)-dependent regulation of pro-inflammatory cytokine production. *Biochem Pharmacol* 63:305–20, PMID: 11841806
78. Haddad JJ (2011) A redox microenvironment is essential for MAPK-dependent secretion of pro-inflammatory cytokines: modulation by glutathione (GSH/GSSG) biosynthesis and equilibrium in the alveolar epithelium. *Cell Immunol* 270:53–61. doi:10.1016/j.cellimm.2011.04.001, PMID: 21550026
79. Gosset P, Wallaert B, Tonnel AB, Fournieu C (1999) Thiol regulation of the production of TNF- α , IL-6 and IL-8 by human alveolar macrophages. *Eur Respir J* 14:98–105
80. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Life P, Holmes D, Bonnefoy JY (1995) Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. *J Exp Med* 182:1785–92, PMID: 7500023
81. Neuschwander-Tetri BA, Bellezzo JM, Britton RS, Bacon BR, Fox ES (1996) Thiol regulation of endotoxin-induced release of tumor necrosis factor α from isolated rat Kupffer cells. *Biochem J* 320: 1005–10
82. Chen CY, Huang YL, Lin TH (1998) Association between oxidative stress and cytokine production in nickel-treated rats. *Arch Biochem Biophys* 356:127–32
83. Helbling B, von Overbeck J, Lauterburg BH (1996) Decreased release of glutathione into the systemic circulation of patients with HIV infection. *Eur J Clin Invest* 26:38–44, PMID: 8682153
84. Brigelius-Flohé R, Banning A, Kny M, Bül G (2004) Redox events in interleukin-1 signaling. *Arch Biochem Biophys* 423:66–73
85. Palamara AT, Perno CF, Aquaro S, Bue MC, Dini L, Garaci E (1996) Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. *AIDS Res Hum Retroviruses* 12:1537–41
86. Novaes R, Freire-de-Lima CG, de Albuquerque RC, Affonso-Mitidieri OR, Espindola O, Lima MA, de Andrada Serpa MJ, Echevarria-Lima J (2013) Modulation of glutathione intracellular levels alters the spontaneous proliferation of lymphocyte from HTLV-1 infected patients. *Immunobiol* 218:1166–74. doi:10.1016/j.imbio.2013.04.002, PMID: 23669236
87. Fratemale A, Paoletti MF, Casabianca A, Orlandi C, Schiavano GF, Chiarantini L, Clayette P, Oiry J, Vogel JU, Cinatl J Jr, Magnani M (2008) Inhibition of murine AIDS by pro-glutathione (GSH) molecules. *Antiviral Res* 77:120–7. doi:10.1016/j.antiviral.2007.11.004
88. Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP (2003) Inhibition of influenza infection by glutathione. *Free Radic Biol Med* 34:928–36, PMID: 12654482
89. Palamara AT, Perno CF, Ciriolo MR, Dini L, Balestra E, D'Agostini C, Di Francesco P, Favalli C, Rotilio G, Garaci E (1995) Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. *Antiviral Res* 27:237–53
90. Garaci E, Palamara AT, Ciriolo MR, D'Agostini C, Abdel-Latif MS, Aquaro S, Lafavia E, Rotilio G (1997) Intracellular GSH content and HIV replication in human macrophages. *J Leukoc Biol* 62:54–59
91. Wang J, Chen Y, Gao N, Wang Y, Tian Y, Wu J, Zhang J, Zhu J, Fan D, An J (2013) Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice. *PLoS One* 8:e55407. doi:10.1371/journal.pone.0055407
92. Tian Y, Jiang W, Gao N, Zhang J, Chen W, Fan D, Zhou D, An J (2010) Inhibitory effects of glutathione on dengue virus production. *Biochem Biophys Res Commun* 397:420–4. doi:10.1016/j.bbrc.2010.05.108
93. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, Clarke F, Sitia R, Rubartelli A (2002) Antigen-presenting dendritic cells provide the reducing extracellular micro-environment required for T lymphocyte activation. *Proc Natl Acad Sci U S A* 99:1491–6, PMID: 11792859
94. Ishii T, Hishinuma I, Bannai S, Sugita Y (1981) Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol. *J Cell Physiol* 107:283–93, PMID: 7251686
95. Yan Z, Garg SK, Kipnis J, Banerjee R (2009) Extracellular redox modulation by regulatory T cells. *Nat Chem Biol* 5:721–3. doi:10.1038/nchembio.212, PMID: 19718041
96. Sido B, Braunstein J, Breitzkreutz R, Herfarth C, Meuer SC (2000) Thiol-mediated redox regulation of intestinal lamina propria T lymphocytes. *J Exp Med* 192:907–12, PMID: 10993921
97. Garg SK, Yan Z, Vitvitsky V, Banerjee R (2011) Differential dependence on cysteine from transsulfuration versus transport during T cell activation. *Antioxid Redox Signal* 15:39–47. doi:10.1089/ars.2010.3496, PMID: 20673163
98. Yan Z, Banerjee R (2010) Redox remodeling as an immunoregulatory strategy. *Biochem* 49:1059–66. doi:10.1021/bi902022n, PMID: 20070126
99. Yan Z, Garg SK, Kipnis J, Banerjee R (2009) Extracellular redox modulation by regulatory T cells. *Nat Chem Biol* 5:721–3. doi:10.1038/nchembio.212, PMID: 19718041
100. Zahedi Avval F, Holmgren A (2009) Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for mammalian S phase ribonucleotide reductase. *J Biol Chem* 284:8233–40. doi:10.1074/jbc.M809338200, PMID: 19176520
101. Suthanthiran M, Anderson ME, Sharma VK, Meister A (1990) Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. *Proc Natl Acad Sci U S A* 87:3343–47, PMID: 1970635
102. Messina JP, Lawrence DA (1989) Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. *J Immunol* 143:1974–81
103. Yan Z, Garg SK, Banerjee R (2010) Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. *J Biol Chem* 285:41525–32. doi:10.1074/jbc.M110.189944, PMID: 21037289
104. Kamide Y, Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Uno K, Hamuro J, Mori M (2011) Intracellular glutathione redox status in human dendritic cells regulates IL-27 production and T-cell polarization. *Allergy* 66:1183–92. doi:10.1111/j.1398-9995.2011.02611.x, PMID: 21545428
105. Murata Y, Ohteki T, Koyasu S, Hamuro J (2002) IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. *Eur J Immunol* 32:2866–73, PMID: 12355439
106. Palomares T, Alonso-Varona A, Alvarez A, Castro B, Calle Y, Bilbao P (1997) Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. *Clin Exp Metastasis* 15:329–37, PMID: 9174132
107. Gmünder H, Roth S, Eck HP, Gallas H, Mihm S, Dröge W (1990) Interleukin-2 mRNA expression, lymphokine production and DNA synthesis in glutathione-depleted T cells. *Cell Immunol* 130:520–8, PMID: 2208308
108. Yamauchi A, Bloom ET (1997) Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. *Blood* 89:4092–9, PMID: 9166850
109. Liang CM, Lee N, Cattell D, Liang SM (1989) Glutathione regulates interleukin-2 activity on cytotoxic T-cells. *J Biol Chem* 264: 13519–23

110. Chen J, Stewart V, Spyrou G, Hilberg F, Wagner EF, Alt FW (1994) Generation of normal T and B lymphocytes by c-jun deficient embryonic stem cells. *Immunity* 1:65–72
111. Pallardó FV, Markovic J, García JL, Viña J (2009) Role of nuclear glutathione as a key regulator of cell proliferation. *Mol Aspects Med* 30:77–85. doi:10.1016/j.mam.2009.01.001, PMID: 19232542
112. Markovic J, García-Giménez JL, Gimeno A, Viña J, Pallardó FV (2010) Role of glutathione in cell nucleus. *Free Radic Res* 44(7): 721–33. doi:10.3109/10715762.2010.485989
113. Diaz Vivancos P, Wolff T, Markovic J, Pallardó FV, Foyer CH (2010) A nuclear glutathione cycle within the cell cycle. *Biochem J* 431:169–78
114. García-Giménez JL, Markovic J, Dasí F, Queval G, Schnaubelt D, Foyer CH, Pallardó FV (2013) Nuclear glutathione. *Biochim Biophys Acta* 1830:3304–16. doi:10.1016/j.bbagen.2012.10.005, PMID: 23069719
115. Ashtiani HRA, Bakhshandi AK, Rahbar M, Mirzaei A, Malekpour A, Rastegar H (2011) Glutathione, cell proliferation and differentiation. *Afr J Biotechnol* 10:6348–63
116. Cuadrado A, García-Fernández LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. *J Biol Chem* 278:241–50, PMID: 12414812
117. Day RM, Suzuki YJ (2006) Cell proliferation, reactive oxygen and cellular glutathione. *Dose Response* 3:425–42. doi:10.2203/dose-response.003.03.010, PMID: 18648617
118. Circu ML, Aw TY (2008) Glutathione and apoptosis. *Free Radic Res* 42:689–706. doi:10.1080/10715760802317663, PMID: 18671159
119. Franco R, Cidlowski JA (2009) Apoptosis and glutathione: beyond an antioxidant. *Cell Death Differ* 16:1303–14. doi:10.1038/cdd.2009.107, PMID: 19662025
120. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. *Cell* 120:483–95, PMID: 15734681
121. Bertout JA, Patel SA, Simon MC (2008) The impact of O₂ availability on human cancer. *Nat Rev Cancer* 8:967–75
122. Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. *Annu Rev Pharmacol Toxicol* 47:143–83, PMID: 17029566
123. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N (2010) Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. *Circ Res* 106:193–202. doi:10.1161/CIRCRESAHA.109.198366, PMID: 19910579
124. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF (2004) Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. *J Neurosci* 24(36):7779–88, PubMed PMID: 15356189
125. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J (2010) NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. *Proc Natl Acad Sci U S A* 107:15565–70. doi:10.1073/pnas.1002178107, PMID: 20713697
126. Adam-Vizi V, Chinopoulos C (2006) Bioenergetics and the formation of mitochondrial reactive oxygen species. *Trends Pharmacol Sci* 27:639–45, PMID: 17056127
127. Andreyev AY, Kushnareva YE, Starkov AA (2005) Mitochondrial metabolism of reactive oxygen species. *Biochemistry (Mosc)* 70: 200–14, PMID: 15807660
128. Murphy MP (2009) How mitochondria produce reactive oxygen species. *Biochem J* 417:1–13. doi:10.1042/BJ20081386, PMID: 19061483
129. Cox AG, Winterbourn CC, Hampton MB (2009) Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. *Biochem J* 425:313–25. doi:10.1042/BJ20091541, PMID: 20025614
130. Aon MA, Cortassa S, O'Rourke B (2010) Redox-optimized ROS balance: a unifying hypothesis. *Biochim Biophys Acta* 1797:865–77. doi:10.1016/j.bbabo.2010.02.016, PMID: 20175987
131. Aon MA, Stanley BA, Sivakumaran V, Kembro JM, O'Rourke B, Paolocci N, Cortassa S (2012) Glutathione/thioredoxin systems modulate mitochondrial H₂O₂ emission: an experimental-computational study. *J Gen Physiol* 139:479–91. doi:10.1085/jgp.201210772, PMID: 22585969
132. Sheeran FL, Rydström J, Shakhparonov MI, Pestov NB, Pepe S (2010) Diminished NADPH transhydrogenase activity and mitochondrial redox regulation in human failing myocardium. *Biochim Biophys Acta* 1797:1138–48. doi:10.1016/j.bbabo.2010.04.002, PMID: 20388492
133. Drechsel DA, Patel M (2010) Respiration-dependent H₂O₂ removal in brain mitochondria via the thioredoxin/peroxiredoxin system. *J Biol Chem* 285:27850–58. doi:10.1074/jbc.M110.101196, PMID: 20558743
134. Go YM, Jones DP (2008) Redox compartmentalization in eukaryotic cells. *Biochim Biophys Acta* 1780:1273–90. doi:10.1016/j.bbagen.2008.01.011, PMID: 18267127
135. Hu J, Dong L, Outten CE (2008) The redox environment in the mitochondrial intermembrane space is maintained separately from the cytosol and matrix. *J Biol Chem* 283:29126–34. doi:10.1074/jbc.M803028200, PMID: 18708636
136. Kakkar P, Singh BK (2007) Mitochondria: a hub of redox activities and cellular distress control. *Mol Cell Biochem* 305:235–53
137. Koehler CM, Beverly K, Leverich EP (2006) Redox pathways in the mitochondrion. *Antioxid Redox Signal* 8:813–22
138. Pedrajas JR, Kosmidou E, Miranda-Vizuet A, Gustafsson JA, Wright AP, Spyrou G (1999) Identification and functional characterization of a novel mitochondrial thioredoxin system in *Saccharomyces cerevisiae*. *J Biol Chem* 274:6366–73
139. Chae HZ, Kang SW, Rhee SG (1999) Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. *Methods Enzymol* 300:219–26
140. Orłowski M, Karkowsky A (1976) Glutathione metabolism and some possible functions of glutathione in the nervous system. *Int Rev Neurobiol* 19:75–121, PMID: 13046
141. Hjelle OP, Rinvik E, Huster D, Reichelt W, Ottersen OP (1998) In: Shaw CA (ed) *Glutathione in the nervous system*. Taylor & Francis, Washington, pp pp. 63–88
142. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. *Science* 258:597–603, PMID: 1329206
143. Récasens M, Mayat E, Vignes M (1992) The multiple excitatory amino acid receptor subtypes and their putative interactions. *Mol Neuropharmacol* 2:15–31
144. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262:689–95, PMID: 7901908
145. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. *Ann Neurol* 38:357–66, PMID: 7668820
146. Ogita K, Shuto M, Maeda H, Minami T, Yoneda Y (1998) Possible modulation by glutathione of glutamatergic neurotransmission. In: Shaw CA (ed) *Glutathione in the nervous system*. Taylor & Francis, Washington, pp pp. 137–161
147. Varga V, Janáky R, Saransaari P, Oja SS (1994) Endogenous gamma-L-glutamyl and beta-L-aspartyl peptides and excitatory aminoacidergic neurotransmission in the brain. *Neuropeptides* 27: 19–26, PMID: 7969817
148. Oja SS, Janáky R, Varga V, Saransaari P (2000) Modulation of glutamate receptor functions by glutathione. *Neurochem Int* 37: 299–306, PMID: 10812215
149. Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997) Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA)

- and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. *Neurochem Res* 22:1165–71, PMID: 9251108
150. Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3 T 1H-MRS study. *PLoS One* 3: e1944, PMID: 18398470
 151. Janáky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA (1999) Glutathione and signal transduction in the mammalian CNS. *J Neurochem* 73:889–902, PMID: 10461878
 152. Varga V, Janáky R, Marnela KM, Gulyás J, Kontro P, Oja SS (1989) Displacement of excitatory amino acid receptor ligands by acidic oligopeptides. *Neurochem Res* 14:1223–7, PMID: 2576463
 153. Jenei Z, Janáky R, Varga V, Saransaari P, Oja SS (1998) Interference of S-alkyl derivatives of glutathione with brain ionotropic glutamate receptors. *Neurochem Res* 23:1085–91, PMID: 9704598
 154. Gilbert KR, Aizenman E, Reynolds IJ (1991) Oxidized glutathione modulates N-methyl-D-aspartate- and depolarization-induced increases in intracellular Ca²⁺ in cultured rat forebrain neurons. *Neurosci Lett* 133:11–4, PMID: 1838798
 155. Cooper AJL (1997) Role of astrocytes in maintaining cerebral glutathione homeostasis and in protecting the brain against xenobiotics and oxidative stress. In: Shaw CA (ed) *Glutathione in the nervous system*. Taylor and Francis, Washington, pp 91–115
 156. Levy DI, Sucher NJ, Lipton SA (1991) Glutathione prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. *Neuroreport* 2: 345–47, PMID: 1832987
 157. Owe SG, Marcaggi P, Attwell D (2006) The ionic stoichiometry of the GLAST glutamate transporter in salamander retinal glia. *J Physiol* 577:591–9, PMID: 17008380
 158. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. *J Neurosci* 15:1835–53, PMID: 7891138
 159. Tanaka K (2000) Functions of glutamate transporters in the brain. *Neurosci Res* 37:15–9, PMID: 10802340
 160. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* 276:1699–1702, PMID: 9180080
 161. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K (2012) L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the ‘collusion’ hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. *J Neuroinflammation* 9:275. doi: [10.1186/1742-2094-9-275](https://doi.org/10.1186/1742-2094-9-275). PMID: 23259598
 162. Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martin R, Zorzano A, Borsani G, Palacin M (2001) Identification and characterisation of human xCT that co-expresses, with 4 F2 heavy chain, the amino acid transport activity system x_c. *Pflügers Arch* 442:286–96
 163. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in cystine/glutamate transporter-deficient mice. *J Biol Chem* 280:37423–9, PMID: 16144837
 164. Allen JW, Shanker G, Aschner M (2001) Methylmercury inhibits the in vitro uptake of the glutathione precursor, cystine, in astrocytes, but not in neurons. *Brain Res* 894:131–40
 165. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M (2006) System X_c- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1–40. *J Neurosci* 26:3345–56, PMID: 16554485
 166. Barger SW, Goodwin ME, Porter MM, Beggs ML (2007) Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. *J Neurochem* 101:1205–13
 167. Kidd PM (2003) Glutathione: Systemic protectant against oxidative and free radical damage. *Alt Med Rev* 2:155–76
 168. Gardner JM, Aust SD (2009) Quantification of hydroxyl radical produced during phacoemulsification. *J Cataract Refract Surg* 35: 2149–53
 169. Sagone AL Jr, Husney RM, O’Dorisio MS, Metz EN (1984) Mechanisms for the oxidation of reduced glutathione by stimulated granulocytes. *Blood* 63:96–104
 170. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA (2009) Nitric oxide in cell survival: a Janus molecule. *Antioxid Redox Signal* 11:2717–39
 171. Chang HL, Dedon PC, Deen WM (2008) Kinetic analysis of intracellular concentrations of reactive nitrogen species. *Chem Res Toxicol* 21:2134–47
 172. Siems W, Crifo C, Capuozzo E, Uchida K, Grune T, Salerno C (2010) Metabolism of 4-hydroxy-2-nonenal in human polymorphonuclear leukocytes. *Arch Biochem Biophys* 503:248–52
 173. Zhu X, Gallogly MM, Mieyal JJ, Anderson VE, Sayre LM (2009) Covalent cross-linking of glutathione and carnosine to proteins by 4-oxo-2-nonenal. *Chem Res Toxicol* 22:1050–9
 174. Lushchak VI (2011) Adaptive response to oxidative stress: bacteria, fungi, plants and animals. *Comp Biochem Physiol C Toxicol Pharmacol* 153:175–190
 175. Lushchak VI (2011) Environmentally induced oxidative stress in aquatic animals. *Aquatic Toxicol* 101:13–30
 176. Belrose JC, Xie YF, Gierszewski LJ, MacDonald JF, Jackson MF (2012) Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons. *Mol Brain* 5:11. doi: [10.1186/1756-6606-5-11](https://doi.org/10.1186/1756-6606-5-11), PMID: 22487454
 177. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. *Biol Chem* 384:505–16
 178. Lu GD, Shen HM, Chung MC, Ong CN (2007) Critical role of oxidative stress and sustained JNK activation in aloe-emodin-mediated apoptotic cell death in human hepatoma cells. *Carcinogenesis* 28:1937–45, PMID: 17698970
 179. Neuschwander-Tetri BA, Bellezzo JM, Britton RS, Bacon BR, Fox ES (1996) Thiol regulation of endotoxin-induced release of tumour necrosis factor alpha from isolated rat Kupffer cells. *Biochem J* 320: 1005–10, PMID: 9003392
 180. Nikulina MA, Andersen HU, Karlsen AE, Darville MI, Eizirik DL, Mandrup-Polusson T (2000) Glutathione depletion inhibits interleukin 1 beta-stimulated nitric oxide production by reducing inducible nitric oxide synthase gene expression. *Cytokine* 12:1391–4
 181. Peristeris P, Clark BD, Gatti S, Faggini R, Mantovani A, Mengozzi M, Orencole SF, Sironi M, Ghezzi P (1992) N-acetylcysteine and glutathione as inhibitors of tumour necrosis factor production. *Cell Immunol* 140:390–9
 182. Robinson MK, Roderick ML, Jacobs DO, Rounds JD, Collins KH, Saporoschetz IB, Mannick JA, Wilmore DW (1993) Glutathione depletion in rats impairs T-cell and macrophage immune function. *Arch Surg* 128:29–35
 183. Komatsu H, Hoshino A, Funayama M, Kawahara K, Obala F (2003) Oxidative modulation of the glutathione-redox couple enhances lipopolysaccharide-induced interleukin 12 P40 production by a mouse macrophage cell line, J774A.1. *Free Radic Res* 37:293–9
 184. Grimbale RF (2006) The effects of sulfur amino acid intake on immune function in humans. *J Nutr* 136:1660S–5S, PMID: 16702336
 185. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. *Proc Natl Acad Sci U S A* 95:3071–6, PMID: 9501217
 186. Won HY, Sohn JH, Min HJ, Lee K, Woo HA, Ho YS, Park JW, Rhee SG, Hwang ES (2010) Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing

- Th2 and Th17 cell development. *Antioxid Redox Signal* 13:575–87. doi:[10.1089/ars.2009.2989](https://doi.org/10.1089/ars.2009.2989), PMID: 20367278
187. Li W, Busu C, Circu ML, Aw TY (2012) Glutathione in cerebral microvascular endothelial biology and pathobiology: implications for brain homeostasis. *Int J Cell Biol* 2012:434971. doi:[10.1155/2012/434971](https://doi.org/10.1155/2012/434971), PMID: 22745639
 188. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, Srivenugopal KS (2007) Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. *Biochem* 46:7765–80, PMID: 17555331
 189. Qanungo S, Starke DW, Pai HV, Mieyal JJ, Nieminen AL (2007) Glutathione supplementation potentiates hypoxic apoptosis by *S*-glutathionylation of p65-NFκB. *J Biol Chem* 282:18427–36, PMID: 17468103
 190. Staal FJ (1998) Glutathione and HIV infection: reduced reduced, or increased oxidized? *Eur J Clin Invest* 28:194–6, PMID: 9568464
 191. Kurdi M, Sivakumaran V, Duhé RJ, Aon MA, Paolocci N, Booz GW (2012) Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes. *Int J Biochem Cell Biol* 44:2106–15. doi:[10.1016/j.biocel.2012.08.016](https://doi.org/10.1016/j.biocel.2012.08.016), PMID: 22939972
 192. Zeevalk GD, Manzano L, Sonsalla PK, Bernard LP (2007) Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. *Exp Neurol* 203(2):512–20, PMID: 17049515
 193. Shen H, Liu Z (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. *Free Rad Biol Med* 40:928–39
 194. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. *Proc Natl Acad Sci U S A* 101:665–70
 195. Garcia-Gimenez JL, Markovic J, Dasi F, Queval G, Schnaubelt D, Foyer CH, Pallardo FV (2013) Nuclear glutathione. *Biochim Biophys Acta* 1830:3304–16
 196. Markovic J, Mora NJ, Broseta AM, Gimeno A, de-la Concepción N, Vina J, Pallardo FV (2009) The depletion of nuclear glutathione impairs cell proliferation in 3 t3 fibroblasts. *PLoS One* 4:e6413. doi:[10.1371/journal.pone.0006413](https://doi.org/10.1371/journal.pone.0006413)
 197. Takahashi T, Tabuchi T, Tamaki Y, Kosaka K, Takikawa Y, Satoh T (2009) Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3 T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism. *Biochem Biophys Res Commun* 382:549–54. doi:[10.1016/j.bbrc.2009.03.059](https://doi.org/10.1016/j.bbrc.2009.03.059), PMID: 19289108
 198. Messina JP, Lawrence DA (1989) Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. *J Immunol* 143:1974–81, PMID: 2789253
 199. Markovic J, Borrás C, Ortega A, Sastre J, Viña J, Pallardo FV (2007) Glutathione is recruited into the nucleus in early phases of cell proliferation. *J Biol Chem* 282:20416–24, PMID: 17452333
 200. Atkuri KR, Cowan TM, Kwan T, Ng A, Herzenberg LA, Herzenberg LA, Enns GM (2009) Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. *Proc Natl Acad Sci U S A* 106:3941–5. doi:[10.1073/pnas.0813409106](https://doi.org/10.1073/pnas.0813409106), PMID: 19223582
 201. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MM (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. *Neuroscience* 149:917–30, PMID: 17936517
 202. Hargreaves IP, Sheena Y, Land JM, Heales SJ (2005) Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. *J Inher Metab Dis* 28:81–8, PMID: 15702408
 203. Pastore A, Pettillo S, Tozzi G, Carozzo R, Martinelli D, Dionisi-Vici C, Di Giovamberardino G, Ceravolo F, Klein MB, Miller G, Enns GM, Bertini E, Piemonte F (2013) Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. *Mol Genet Metab* 109:208–14. doi:[10.1016/j.ymgme.2013.03.011](https://doi.org/10.1016/j.ymgme.2013.03.011), PMID: 23583222
 204. Salmi H, Leonard JV, Rahman S, Lapatto R (2012) Plasma thiol status is altered in children with mitochondrial diseases. *Scand J Clin Lab Invest* 72:152–7. doi:[10.3109/00365513.2011.646299](https://doi.org/10.3109/00365513.2011.646299), PMID: 22208644
 205. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) *N*-acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7:355–9, PMID: 17602868
 206. Waly MI, Hornig M, Trivedi M, Hodgson N, Kini R, Ohta A, Deth R (2012) Prenatal and postnatal epigenetic programming: implications for GI, immune, and neuronal function in autism. *Autism Res Treat* 2012:190930. doi:[10.1155/2012/190930](https://doi.org/10.1155/2012/190930), PMID: 22934169
 207. Kang PT, Zhang L, Chen CL, Chen J, Green KB, Chen YR (2012) Protein thiol radical mediates *S*-glutathionylation of complex I. *Free Radic Biol Med* 53:962–73. doi:[10.1016/j.freeradbiomed.2012.05.025](https://doi.org/10.1016/j.freeradbiomed.2012.05.025), PMID: 22634394
 208. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD (2009) Novel role for glutathione *S*-transferase piRegulator of protein *S*-glutathionylation following oxidative and nitrosative stress. *J Biol Chem* 284:436–45. doi:[10.1074/jbc.M805586200](https://doi.org/10.1074/jbc.M805586200), PMID: 18990698
 209. Borutaite V, Brown GC (2007) Mitochondrial regulation of caspase activation by cytochrome oxidase and tetramethylphenylenediamine via cytosolic cytochrome c redox state. *J Biol Chem* 282:31124–30, PMID: 17690099
 210. Vaughn AE, Deshmukh M (2008) Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. *Nat Cell Biol* 10:1477–83. doi:[10.1038/ncb1807](https://doi.org/10.1038/ncb1807), PMID: 19029908
 211. Kizhakkayil J, Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S (2012) Glutathione regulates caspase-dependent ceramide production and curcumin-induced apoptosis in human leukemic cells. *Free Radic Biol Med* 52:1854–64. doi:[10.1016/j.freeradbiomed.2012.02.026](https://doi.org/10.1016/j.freeradbiomed.2012.02.026), PMID: 22387197
 212. Martín SF, Sawai H, Villalba JM, Hannun YA (2007) Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. *Arch Biochem Biophys* 459:295–300, PMID: 17169322
 213. Lou H, Kaplowitz N (2007) Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-κB activity via IκB kinase-dependent and -independent mechanisms. *J Biol Chem* 282:29470–81, PMID: 17690092
 214. Franco R, Cidlowski JA (2009) Apoptosis and glutathione: beyond an antioxidant. *Cell Death Differ* 16:1303–14. doi:[10.1038/cdd.2009.107](https://doi.org/10.1038/cdd.2009.107), PMID: 19662025
 215. Allen EM, Mieyal JJ (2012) Protein-thiol oxidation and cell death: regulatory role of glutaredoxins. *Antioxid Redox Signal* 17:1748–63. doi:[10.1089/ars.2012.4644](https://doi.org/10.1089/ars.2012.4644), PMID: 22530666
 216. Franco R, Panayiotidis MI, Cidlowski JA (2007) Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. *J Biol Chem* 282:30452–65, PMID: 17724027
 217. Ji L, Shen K, Jiang P, Morahan G, Wang Z (2011) Critical roles of cellular glutathione homeostasis and jnk activation in andrographolide-mediated apoptotic cell death in human hepatoma cells. *Mol Carcinog* 50:580–91. doi:[10.1002/mc.20741](https://doi.org/10.1002/mc.20741), PMID: 21319226
 218. Yue P, Zhou Z, Khuri FR, Sun SY (2006) Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). *Cancer Biol Ther* 5:492–7, PMID: 16582599

219. Haouzi D, Lekehal M, Tinel M, Vadrot N, Caussanel L, Lett eron P, Moreau A, Feldmann G, Fau D, Pessayre D (2001) Prolonged, but not acute, glutathione depletion promotes Fas-mediated mitochondrial permeability transition and apoptosis in mice. *Hepatology* 33: 1181–8
220. Armstrong JS, Jones DP (2002) Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. *FASEB J* 16:1263–5, PMID: 12060676
221. Chernyak BV (1997) Redox regulation of the mitochondrial permeability transition pore. *Biosci Rep* 17:293–302, PMID: 9337484
222. Sato T, Machida T, Takahashi S, Iyama S, Sato Y, Kuribayashi K, Takada K, Oku T, Kawano Y, Okamoto T, Takimoto R, Matsunaga T, Takayama T, Takahashi M, Kato J, Niitsu Y (2004) Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. *J Immunol* 173:285–96, PMID: 15210786
223. D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, Ghibelli L (2005) Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. *FASEB J* 19:1504–6, PMID: 15972297
224. Kanno T, Nishizaki T (2001) Sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via a mitochondrial pathway linked to SDK/14-3-3 protein/Bax/cytochrome c. *J Cell Physiol* 226:2329–37. doi:10.1002/jcp.22571, PMID: 21660956
225. Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK (2011) Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. *J Pharmacol Exp Ther* 336:206–14. doi:10.1124/jpet.110.171983, PMID: 20876229
226. Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Rimessi A, Suski JM, Wieckowski MR, Pinton P (2012) Mitochondrial Ca(2+) and apoptosis. *Cell Calcium* 52:36–43. doi:10.1016/j.ceca.2012.02.008, PMID: 22480931
227. Jin M, Yaung J, Kannan R, He S, Ryan SJ, Hinton DR (2005) Hepatocyte growth factor protects RPE cells from apoptosis induced by glutathione depletion. *Invest Ophthalmol Vis Sci* 46: 4311–19, PMID: 16249513
228. Robillard JM, Gordon GR, Choi HB, Christie BR, MacVicar BA (2011) Glutathione restores the mechanism of synaptic plasticity in aged mice to that of the adult. *PLoS One* 6:e20676. doi:10.1371/journal.pone.0020676, PMID: 21655192
229. Steullet P, Neijt HC, Cu  n  d M, Do KQ (2006) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. *Neuroscience* 137: 807–19, PMID: 16330153
230. Abramov AY, Canevari L, Duchon MR (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. *J Neurosci* 23:5088–95, PMID: 12832532
231. Dallas M, Boycott HE, Atkinson L, Miller A, Boyle JP, Pearson HA, Peers C (2007) Hypoxia suppresses glutamate transport in astrocytes. *J Neurosci* 27:3946–55, PMID: 17428968
232. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron* 2:1547–58, PMID: 2576375
233. Juurlink BH (1997) Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. *Neurosci Biobehav Rev* 21:151–66, PMID: 9062938
234. Stewart VC, Stone R, Gegg ME, Sharpe MA, Hurst RD, Clark JB, Heales SJ (2002) Preservation of extracellular glutathione by an astrocyte derived factor with properties comparable to extracellular superoxide dismutase. *J Neurochem* 83:984–91, PMID: 12421371
235. Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the anti-oxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. *J Neurosci* 19:562–9, PMID: 9880576
236. Dringen R, Gutterer JM, Gros C, Hirrlinger J (2001) Amino-peptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. *J Neurosci Res* 66:1003–8, PMID: 11746430
237. Aoyama K, Watabe M, Nakaki T (2008) Regulation of neuronal glutathione synthesis. *J Pharmacol Sci* 108:227–38, PMID: 19008644
238. Lertratanangkoon K, Wu CJ, Savaraj N, Thomas ML (1997) Alterations of DNA methylation by glutathione depletion. *Cancer Lett* 120:149–56, PMID: 9461031
239. Campos AC, Molognoni F, Melo FH, Galdieri LC, Cameiro CR, D'Almeida V, Correa M, Jasiulionis MG (2007) Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. *Neoplasia* 9:1111–21, PMID: 18084618
240. Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. *Carcinogenesis* 33:723–31. doi:10.1093/carcin/bgs006, PMID: 22235026
241. Wachsman JT (1997) DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. *Mutat Res* 375:1–8, PMID: 9129674
242. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K (1994) Free radical adducts induce alterations in DNA cytosine methylation. *Proc Natl Acad Sci U S A* 91:1261–4, PMID: 8108398
243. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtsuka E, Nishimura S (1987) Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. *Nature* 327:77–9, PMID: 3574469
244. Hitchler MJ, Domann FE (2007) An epigenetic perspective on the free radical theory of development. *Free Radic Biol Med* 43:1023–36, PMID: 17761298
245. McCaddon A, Regland B, Hudson P, Davies G (2002) Functional vitamin B(12) deficiency and Alzheimer disease. *Neurology* 58: 1395–9, PMID: 12011287
246. Deth R, Muratore C, Benzecry J, Power-Chamitsky VA, Waly M (2008) How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. *Neurotoxicol* 29:190–201, PMID: 1803-1821
247. Looney JM, Childs HM (1934) The lactic acid and glutathione content of the blood of schizophrenic patients. *J Clin Invest* 13: 963–8, PMID: 16694262
248. Rybka J, K  dziora-Komatowska K, Bana  s-Le  a  ska P, Majsterek I, Carvalho LA, Cattaneo A, Anacker C, K  dziora J (2013) Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. *Free Radic Biol Med* 63:187–194. doi:10.1016/j.freeradbiomed.2013.05.019, PMID: 23707456
249. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2011) Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. *Neuro Endocrinol Lett* 32:133–40, PMID: 21552194
250. Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W (2012) Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. *Sci Rep* 2:667, PMID: 22993692
251. Stefanescu C, Ciobica A (2012) The relevance of oxidative stress status in first episode and recurrent depression. *J Affect Disorder* 20;143(1-3):34–8. doi:10.1016/j.jad.2012.05.022

252. Gibson SA, Korade Ž, Shelton RC (2012) Oxidative stress and glutathione response in tissue cultures from persons with major depression. *J Psychiatr Res* 46:1326–32. doi:[10.1016/j.jpsychires.2012.06.008](https://doi.org/10.1016/j.jpsychires.2012.06.008), PMID: 22841833
253. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT (2011) Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. *Int J Neuropsychopharmacol* 14:1069–74. doi:[10.1017/S1461145711000617](https://doi.org/10.1017/S1461145711000617), PMID: 21733244
254. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011) Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J Neuropsychopharmacol* 14:123–30. doi:[10.1017/S1461145710000805](https://doi.org/10.1017/S1461145710000805), PMID: 20633320
255. Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, James SJ (2012) Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. *Transl Psychiatry* 2:e134. doi:[10.1038/tp.2012.61](https://doi.org/10.1038/tp.2012.61), PMID: 22781167
256. Mathew SJ, Murrough JW, Mao X, Pillemer S, Shungu DC (2010) Proton magnetic resonance spectroscopy measurement of brain glutathione supports increased oxidative stress in major depressive disorder. 49th American College of Neuropsychopharmacology Annual Meeting, Miami, FL, December 5. Poster Session 1: 153
257. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. *Eur J Neurosci* 12:3721–8, PMID: 11029642
258. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3 T 1H-MRS study. *PLoS One* 3:e1944, PMID: 18398470
259. Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O (2011) Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. *J Affect Disord* 131: 207–13. doi:[10.1016/j.jad.2010.12.019](https://doi.org/10.1016/j.jad.2010.12.019), PMID: 21277635
260. Maes M, Van de Vyvere J, Vandoolaeghe E, Bril T, Demedts P, Wauters A, Neels H (1996) Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process. *J Affect Disord* 40:23–33. doi:[10.1016/0165-0327\(96\)00038-9](https://doi.org/10.1016/0165-0327(96)00038-9), PMID: 8882911
261. Edwards R, Peet M, Shay J, Horrobin D (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affect Disord* 48:149–55. doi:[10.1016/S0165-0327\(97\)00166-3](https://doi.org/10.1016/S0165-0327(97)00166-3), PMID: 9543204
262. Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 43:315–9, PMID: 9513745
263. Richards RS, Wang L, Jelinek H (2007) Erythrocyte oxidative damage in chronic fatigue syndrome. *Arch Med Res* 38:94–8
264. Raftos JE, Whillier S, Kuchel PW (2010) Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data. *J Biol Chem* 285: 23557–67. doi:[10.1074/jbc.M109.067017](https://doi.org/10.1074/jbc.M109.067017), PMID: 20498365
265. Tavazzi B, Amorini AM, Fazzina G, Di Pierro D, Tuttobene M, Giardina B, Lazzarino G (2001) Oxidative stress induces impairment of human erythrocyte energy metabolism through the oxygen radical-mediated direct activation of AMP-deaminase. *J Biol Chem* 276:48083–92, PMID: 11675377
266. Pandey KB, Rizvi SI (2010) Markers of oxidative stress in erythrocytes and plasma during aging in humans. *Oxid Med Cell Longev* 3: 2–12. doi:[10.4161/oxim.3.1.10476](https://doi.org/10.4161/oxim.3.1.10476), PMID: 20716923
267. Morris G, Maes M (2013) Case definitions and diagnostic criteria for myalgic encephalomyelitis and chronic fatigue syndrome: from clinical-consensus to evidence-based case definitions. *Neuro-Endocrinol Lett* 34:185–99, PMID: 23685416
268. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ (2012) Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR Biomed* 25:1073–87. doi:[10.1002/nbm.2772](https://doi.org/10.1002/nbm.2772), PMID: 22281935
269. Puri BK, Agour M, Gunatilake KD, Fernando KA, Gurusinghe AI, Treasaden IH (2009) An in vivo proton neurospectroscopy study of cerebral oxidative stress in myalgic encephalomyelitis (chronic fatigue syndrome). *Prostaglandins Leukot Essent Fatty Acids* 81: 303–5. doi:[10.1016/j.plefa.2009.10.002](https://doi.org/10.1016/j.plefa.2009.10.002), PMID: 19906518
270. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ (2005) Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. *Free Radic Biol Med* 39:584–9, PMID: 16085177
271. Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt HL (2000) Free radicals in chronic fatigue syndrome: cause or effect? *Redox Rep* 5:146–7
272. Fulle S, Mecocci P, Fanó G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000) Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. *Free Radic Biol Med* 29:1252–9, PMID: 11118815
273. Logan AC, Wong C (2001) Chronic fatigue syndrome: oxidative stress and dietary modifications. *Altern Med Rev* 6:450–9, PMID: 11703165
274. Jammes Y, Steinberg JG, Mambrini O, Brégeon F, Delliaux S (2005) Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. *J Intern Med* 257:299–310, PMID: 15715687
275. Bested AC, Saunders PR, Logan AC (2001) Chronic fatigue syndrome: neurological findings may be related to blood-brain barrier permeability. *Med Hypotheses* 57:231–7, PMID: 11461179
276. Kim HG, Cho JH, Yoo SR, Lee JS, Han JM, Lee NH, Ahn YC, Son CG (2013) Antifatigue effects of *Panax ginseng* C.A. Meyer: a randomised, double-blind, placebo-controlled trial. *PLoS One* 8: e61271
277. Kim HG, Yoo SR, Park HJ, Son CG (2013) Indirect moxibustion (CV4 and CV8) ameliorates chronic fatigue: a randomized, double-blind, controlled study. *J Altern Complement Med* 19:134–40. doi:[10.1089/acm.2011.0503](https://doi.org/10.1089/acm.2011.0503), PMID: 22757691
278. Ding W, Liu Y (2011) Genistein attenuates genioglossus muscle fatigue under chronic intermittent hypoxia by down-regulation of oxidative stress level and up-regulation of antioxidant enzyme activity through ERK1/2 signaling pathway. *Oral Dis* 17:677–84. doi:[10.1111/j.1601-0825.2011.01822.x](https://doi.org/10.1111/j.1601-0825.2011.01822.x), PMID: 21729219
279. Liu CZ, Lei B (2012) Effect of acupuncture on serum malonaldehyde content, superoxide dismutase and glutathione peroxidase activity in chronic fatigue syndrome rats. *Zhen Ci Yan Jiu* 37:38–40, PMID: 22574567
280. Sachdeva AK, Kuhad A, Tiwari V, Chopra K (2009) Epigallocatechin gallate ameliorates chronic fatigue syndrome in mice: behavioral and biochemical evidence. *Behav Brain Res* 205: 414–20. doi:[10.1016/j.bbr.2009.07.020](https://doi.org/10.1016/j.bbr.2009.07.020), PMID: 19643148
281. Kumar A, Garg R (2009) Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. *Fundam Clin Pharmacol* 23:89–95. doi:[10.1111/j.1472-8206.2008.00638.x](https://doi.org/10.1111/j.1472-8206.2008.00638.x), PMID: 19207541
282. Kumar A, Garg R (2008) Kumar P (2008) Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome. *Pharmacol Rep* 60(5):664–72, PubMed PMID: 19066412
283. Dhir A, Kulkarni SK (2008) Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. *Pharmacol, Biochem Behav* 89:563–71. doi:[10.1016/j.pbb.2008.02.011](https://doi.org/10.1016/j.pbb.2008.02.011), PMID: 18336891

284. Singal A, Kaur S, Tirkey N, Chopra K (2005) Green tea extract and catechin ameliorate chronic fatigue-induced oxidative stress in mice. *J Med Food* 8:47–52, PMID: 15857209
285. Singh A, Garg V, Gupta S, Kulkarni SK (2002) Role of antioxidants in chronic fatigue syndrome in mice. *Indian J Exp Biol* 40:1240–4, PMID:13677625
286. Morris G, Maes M (2013) Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. *BMC Med* 11:205. doi:[10.1186/1741-7015-11-205](https://doi.org/10.1186/1741-7015-11-205), PMID: 24229326
287. Morris G, Maes M (2014) Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. *Metab Brain Dis* 29(1):19–36
288. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 35(3):744–59. doi:[10.1016/j.pnpbp.2010.08.026](https://doi.org/10.1016/j.pnpbp.2010.08.026), PubMed PMID: 20828592
289. Vialou V, Feng J, Robison AJ, Nestler EJ (2013) Epigenetic mechanisms of depression and antidepressant action. *Annu Rev Pharmacol Toxicol* 53:59–87. doi:[10.1146/annurev-pharmtox-010611-134540](https://doi.org/10.1146/annurev-pharmtox-010611-134540), PMID: 23020296
290. Menzies V, Lyon DE, Archer KJ, Zhou Q, Brumelle J, Jones KH, Gao G, York TP, Jackson-Cook C (2013) Epigenetic alterations and an increased frequency of micronuclei in women with fibromyalgia. *Nurs Res Pract* 2013:795784. doi:[10.1155/2013/795784](https://doi.org/10.1155/2013/795784), PMID: 24058735
291. Rönnbäck L, Hansson E (2004) On the potential role of glutamate transport in mental fatigue. *J Neuroinflammation* 1:22, PMID: 15527505
292. Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry* 18:595–606. doi:[10.1038/mp.2012.33](https://doi.org/10.1038/mp.2012.33), PMID: 22525486
293. Anderson G, Maes M (2013) Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. *Curr Pharm Des* [Epub ahead of print] PubMed PMID: 24180395.
294. Keane PC, Kurzawa M, Blain PG, Morris CM (2011) Mitochondrial dysfunction in Parkinson's disease. *Parkinsons Dis* 2011:716871. doi:[10.4061/2011/716871](https://doi.org/10.4061/2011/716871), PMID: 21461368
295. Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J (2005) Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. *J Neurochem* 92:1091–103, PMID: 15715660
296. Auchère F, Santos R, Planamente S, Lesuisse E, Camadro JM (2008) Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. *Hum Mol Genet* 17: 2790–802. doi:[10.1093/hmg/ddn178](https://doi.org/10.1093/hmg/ddn178), PMID: 18562474
297. Friedlich AL, Smith MA, Zhu X, Takeda A, Nunomura A, Moreira PI, Perry G (2009) Oxidative stress in Parkinson's disease. *Open Pathology J* 3:38–42
298. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. *Toxicology* 283:65–87. doi:[10.1016/j.tox.2011.03.001](https://doi.org/10.1016/j.tox.2011.03.001), PMID: 21414382
299. Valko M, Morris H, Cronin MT (2005) Metals, toxicity and oxidative stress. *Curr Med Chem* 12:1161–208, PMID: 15892631
300. Morris G, Maes M (2014) Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. *Metab Brain Dis* 29:19–36. doi:[10.1007/s11011-013-9435-x](https://doi.org/10.1007/s11011-013-9435-x), PMID: 24557875
301. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA (2007) Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. *Pulm Pharmacol Ther* 20:9–22, PMID: 16458553
302. Cotgreave IA (1997) *N*-acetylcysteine: pharmacological considerations and experimental and clinical applications. *Adv Pharmacol* 38:205–27, PMID: 8895810
303. Jain A, Mårtensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. *Proc Natl Acad Sci U S A* 88:1913–7, PMID: 2000395
304. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? *Biomed Pharmacother* 62:236–49
305. De Flora S, Bennicelli C, Camoirano A, Serra D, Romano M, Rossi GA, Morelli A, De Flora A (1985) In vivo effects of *N*-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. *Carcinogenesis* 6:1735–45
306. Hoffer E, Baum Y, Tabak A, Taitelman U (1996) *N*-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. *Toxicol Lett* 84:7–12
307. Corcoran GB, Wong BK (1986) Role of glutathione in prevention of acetaminophen-induced hepatotoxicity by *N*-acetyl-L-cysteine in vivo: studies with *N*-acetyl-D-cysteine in mice. *J Pharmacol Exp Ther* 238:54–61
308. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) *N*-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7:355–9
309. Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of *N*-acetylcysteine. *Biochim Biophys Acta* 1830:4117–29. doi:[10.1016/j.bbagen.2013.04.016](https://doi.org/10.1016/j.bbagen.2013.04.016)
310. Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M (2008) The glutathione precursor *N*-acetylcysteine improves immune function in postmenopausal women. *Free Radic Biol Med* 45:1252–62. doi:[10.1016/j.freeradbiomed.2008.07.014](https://doi.org/10.1016/j.freeradbiomed.2008.07.014)
311. Banner W Jr, Koch M, Capin DM, Hopf SB, Chang S, Tong TG (1986) Experimental chelation therapy in chromium, lead, and boron intoxication with *N*-acetylcysteine and other compounds. *Toxicol Appl Pharmacol* 83:142–7
312. de Quay B, Malinverni R, Lauterburg BH (1992) Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral *N*-acetylcysteine. *AIDS* 6:815–9
313. Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad AC, Rasool O (1996) Effect of *n*-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. *Eur J Clin Pharmacol* 50:457–61
314. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, Deresinski SC, Herzenberg LA (1997) Glutathione deficiency is associated with impaired survival in HIV disease. *Proc Natl Acad Sci U S A* 94:1967–72
315. Chen F, Lewis W, Hollander JM, Baseler W, Finkel MS (1985) *N*-acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy. *J Appl Physiol* 113:105–13. doi:[10.1152/japplphysiol.00068.2012](https://doi.org/10.1152/japplphysiol.00068.2012)
316. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaizt I, Anderson-Hunt M, Bush AI (2008) *N*-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. *Biol Psychiatry* 64:468–75. doi:[10.1016/j.biopsych.2008.04.022](https://doi.org/10.1016/j.biopsych.2008.04.022), PMID: 18534556
317. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaizt I, Anderson-Hunt M, Berk M (2011) *N*-acetylcysteine for major depressive episodes in bipolar disorder. *Rev Bras Psiquiatr* 33:374–8, PMID: 22189927
318. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaizt I, Dodd S, Malhi GS (2011) The efficacy of *N*-

- acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. *J Affect Disord* 135:389–94. doi:10.1016/j.jad.2011.06.005
319. Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekhehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S (2013) *N*-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. *Clin Neuropharmacol* 36:185–92
 320. Ghanizadeh A, Moghimi-Sarani E (2013) A randomized double blind placebo controlled clinical trial of *N*-acetylcysteine added to risperidone for treating autistic disorders. *BMC Psychiatry* 13:196. doi:10.1186/1471-244X-13-196
 321. Child DF, Hudson PR, Jones H, Davies GK, De P, Mukherjee S, Brain AM, Williams CP, Harvey JN (2004) The effect of oral folic acid on glutathione, glycaemia and lipids in type 2 diabetes. *Diabetes Nutr Metab* 17:95–102
 322. Chanson A, Rock E, Martin JF, Liotard A, Brachet P (2007) Preferential response of glutathione-related enzymes to folate-dependent changes in the redox state of rat liver. *Eur J Nutr* 46:204–12
 323. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M (2012) L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry* 169:1267–74
 324. Reynolds EH (2002) Folic acid, ageing, depression, and dementia. *BMJ* 324:1512–5, PMID: 12077044
 325. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba BM, Diana R, La Greca P, Le Grazie C (1993) Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. *Aging* 5:63–71
 326. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T (1997) Folate, vitamin B12, and homocysteine in major depressive disorder. *Am J Psychiatry* 154:426–8
 327. Guaraldi GP, Fava M, Mazzi F, la Greca P (1993) An open trial of methyltetrahydrofolate in elderly depressed patients. *Ann Clin Psychiatry* 5:101–5
 328. Stahl SM (2007) Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. *CNS Spectr* 12:739–44, PMID: 17934378
 329. Liu J (2008) The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. *Neurochem Res* 33:194–203
 330. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA (2012) Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. *Obesity (Silver Spring)* 20:1974–83
 331. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2008) Functions of coenzyme Q10 in inflammation and gene expression. *Biofactors* 32:179–83
 332. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009) Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. *Neuro-Endocrinol Lett* 30:462–9
 333. Aboul-Fotouh S (2013) Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. *Pharmacol, Biochem Behav* 104:105–12
 334. Forester BP, Zuo CS, Ravichandran C, Harper DG, Du F, Kim S, Cohen BM, Renshaw PF (2012) Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. *J Geriatr Psychiatry Neurol* 25:43–50. doi:10.1177/0891988712436688, PMID: 22467846
 335. Jeong YY, Park HJ, Cho YW, Kim EJ, Kim GT, Mun YJ, Lee JD, Shin JH, Sung NJ, Kang D, Han J (2012) Aged red garlic extract reduces cigarette smoke extract-induced cell death in human bronchial smooth muscle cells by increasing intracellular glutathione levels. *Phytother Res* 26:18–25. doi:10.1002/ptr.3502
 336. Rodríguez-Ramiro I, Ramos S, Bravo L, Goya L, Martín MÁ (2011) Procyanidin B2 and a cocoa polyphenolic extract inhibit acrylamide-induced apoptosis in human Caco-2 cells by preventing oxidative stress and activation of JNK pathway. *J Nutr Biochem* 22:1186–94. doi:10.1016/j.jnutbio.2010.10.005
 337. Kansanen E, Kuosmanen SM, Leinonen H, Levenon AL (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. *Redox Biol* 1:45–9, PMID: 24024136
 338. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. *Inflammopharmacol* 20:127–50
 339. Nguyen T, Sherratt PJ, Pickett CB (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu Rev Pharmacol Toxicol* 43:233–60
 340. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc Natl Acad Sci U S A* 99:11908–13
 341. Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. *Free Radic Biol Med* 46:443–53. doi:10.1016/j.freeradbiomed.2008.10.040
 342. Tsai CC, Chen HS, Chen SL, Ho YP, Ho KY, Wu YM, Hung CC (2005) Lipid peroxidation: a possible role in the induction and progression of chronic periodontitis. *J Periodontol Res* 40:378–84
 343. Dias VV, Brissos S, Cardoso C, Andreazza AC, Kapczinski F (2009) Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. *J Affect Disord* 113:285–90
 344. Godman CA, Chheda KP, Hightower LE, Perdrizet G, Shin DG, Giardina C (2010) Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. *Cell Stress Chaperones* 15:431–42
 345. Thom SR (1985) Oxidative stress is fundamental to hyperbaric oxygen therapy. *J Appl Physiol* 106:988–95. doi:10.1152/japplphysiol.91004.2008, PMID: 18845776
 346. Soejima Y, Ostrowski RP, Manaenko A, Fujii M, Tang J, Zhang JH (2012) Hyperbaric oxygen preconditioning attenuates hyperglycemia enhanced hemorrhagic transformation after transient MCAO in rats. *Med Gas Res* 2:9
 347. Avtan SM, Kaya M, Orhan N, Arslan A, Arican N, Toklu AS, Gürses C, Elmas I, Kucuk M, Ahishali B (2011) The effects of hyperbaric oxygen therapy on blood-brain barrier permeability in septic rats. *Brain Res* 1412:63–72. doi:10.1016/j.brainres.2011.07.020
 348. Haapaniemi T, Sirsjo A, Nylander G, Larsson J (1995) Hyperbaric oxygen treatment attenuates glutathione depletion and improves metabolic restitution in postischemic skeletal muscle. *Free Radic Res* 23:91–101
 349. Purucker E, Lutz J (1992) Effect of hyperbaric oxygen treatment and perfluorochemical administration on glutathione status of the lung. *Adv Exp Med Biol* 317:131–6
 350. Li Q, Li J, Zhang L, Wang B, Xiong L (2007) Preconditioning with hyperbaric oxygen induces tolerance against oxidative injury via

- increased expression of heme oxygenase-1 in primary cultured spinal cord neurons. *Life Sci* 80:1087–93. doi:[10.1016/j.lfs.2006.11.043](https://doi.org/10.1016/j.lfs.2006.11.043)
351. Rothfuss A, Speit G (2002) Investigations on the mechanism of hyperbaric oxygen (HBO)-induced adaptive protection against oxidative stress. *Mutat Res* 508:157–65
 352. Speit G, Dennog C, Eichhorn U, Rothfuss A, Kaina B (2000) Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treatment. *Carcinogenesis* 21:1795–9
 353. Surh YJ, Kundu JK, Na HK (2008) Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. *Planta Med* 74:1526–39
 354. Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I (2005) Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. *Antioxid Redox Signal* 7:32–41
 355. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I (2008) Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 294:L478–488
 356. Garg R, Gupta S, Maru GB (2008) Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. *Carcinogenesis* 29:1022–32
 357. Natarajan VT, Singh A, Kumar AA (2010) Transcriptional upregulation of Nrf2-dependent phase II detoxification genes in the involved epidermis of vitiligo vulgaris. *J Invest Dermatol* 130:2781–9
 358. Shen G, Xu C, Hu R (2006) Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. *Mol Cancer Ther* 5:39–51
 359. McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ (2007) Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. *Int J Mol Med* 19:165–72
 360. Rushworth SA, Ogborne RM, Charalambos CA, O'Connell MA (2006) Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. *Biochem Biophys Res Commun* 341:1007–16
 361. Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB (2013) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. *Phytother Res* doi: [10.1002/ptr.5025](https://doi.org/10.1002/ptr.5025)
 362. Kulkarni S, Dhir A, Akula KK (2009) Potentials of curcumin as an antidepressant. *Sci World J* 9:1233–41. doi:[10.1100/tsw.2009.137](https://doi.org/10.1100/tsw.2009.137)
 363. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K (2009) Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. *Immunobiol* 214:33–9
 364. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A (2004) Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. *J Biol Chem* 279:8919–29
 365. Kong AN, Yu R, Hebbar V, Chen C, Owuor E, Hu R, Ee R, Mandlekar S (2001) Signal transduction events elicited by cancer prevention compounds. *Mutat Res* 480–481:231–41
 366. Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y, Sun Z, Zhang DD (2008) Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. *Free Radic Biol Med* 45:385–95
 367. Moriya J, Chen R, Yamakawa J, Sasaki K, Ishigaki Y, Takahashi T (2011) Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. *Biol Pharm Bull* 34:354–9
 368. Niu K, Hozawa A, Kuriyama S, Ebihara S, Guo HM, Nakaya N, Ohmori-Matsuda K, Takahashi H, Masamune Y, Asada M, Sasaki S, Arai H, Awata S, Nagatomi R, Tsuji I (2009) Green tea consumption is associated with depressive symptoms in the elderly. *Am J Clin Nutr* 90:1615–22
 369. Han SG, Han SS, Toborek M, Hennig B (2012) EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. *Toxicol Appl Pharmacol* 261:181–8
 370. Steele ML, Fuller S, Patel M, Kersaitis C, Ooi L, Münch G (2013) Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. *Redox Biol* 1: 441–5. doi:[10.1016/j.redox.2013.08.006](https://doi.org/10.1016/j.redox.2013.08.006)
 371. Lin SX, Lisi L, Russo CD, Polak PE, Sharp A, Weinberg G, Kalinin S, Feinstein DL (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. *ASN Neuro* 3:e00055. doi:[10.1042/AN20100033](https://doi.org/10.1042/AN20100033)
 372. Lukashev M, Zeng M, Goelz S, Lee D, Linker R, Drukach B, VanDam A (2007) Activation of Nrf2 and modulation of disease progression in EAE models by BG-12 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. *Mult Scler* 13:149
 373. Linker RA, Gold R (2013) Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. *Curr Neurol Neurosci Rep* 13:394. doi:[10.1007/s11910-013-0394-8](https://doi.org/10.1007/s11910-013-0394-8)
 374. Moharreh-Khiabani D, Linker RA, Gold R, Stangel M (2009) Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. *Curr Neuroparmacol* 7:60–64. doi:[10.2174/157015909787602788](https://doi.org/10.2174/157015909787602788)
 375. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neil GN, BG-12 Phase IIb Study Investigators (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet* 372:1463–72
 376. Dodd S, Maes M, Anderson G, Dean O, Moylan S, Berk M (2013) Putative neuroprotective agents in major psychoses. *Prog Neuropsychopharmacol Biol Psychiatry* 42:135–145